Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.Heart Atria: The chambers of the heart, to which the BLOOD returns from the circulation.Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.Anti-Arrhythmia Agents: Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.Pulmonary Veins: The veins that return the oxygenated blood from the lungs to the left atrium of the heart.Electric Countershock: An electrical current applied to the HEART to terminate a disturbance of its rhythm, ARRHYTHMIAS, CARDIAC. (Stedman, 25th ed)Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.Atrial Flutter: Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).Anticoagulants: Agents that prevent clotting.Electrocardiography: Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.Electrophysiologic Techniques, Cardiac: Methods to induce and measure electrical activities at specific sites in the heart to diagnose and treat problems with the heart's electrical system.Atrial Appendage: Ear-shaped appendage of either atrium of the heart. (Dorland, 28th ed)Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.Cardiac Pacing, Artificial: Regulation of the rate of contraction of the heart muscles by an artificial pacemaker.Heart Conduction System: An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)Refractory Period, Electrophysiological: The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.Tachycardia, Paroxysmal: Abnormally rapid heartbeats with sudden onset and cessation.Atrial Function: The hemodynamic and electrophysiological action of the HEART ATRIA.Atrial Function, Left: The hemodynamic and electrophysiological action of the LEFT ATRIUM.Recurrence: The return of a sign, symptom, or disease after a remission.Atrial Premature Complexes: A type of cardiac arrhythmia with premature atrial contractions or beats caused by signals originating from ectopic atrial sites. The ectopic signals may or may not conduct to the HEART VENTRICLES. Atrial premature complexes are characterized by premature P waves on ECG which are different in configuration from the P waves generated by the normal pacemaker complex in the SINOATRIAL NODE.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.Electrocardiography, Ambulatory: Method in which prolonged electrocardiographic recordings are made on a portable tape recorder (Holter-type system) or solid-state device ("real-time" system), while the patient undergoes normal daily activities. It is useful in the diagnosis and management of intermittent cardiac arrhythmias and transient myocardial ischemia.Body Surface Potential Mapping: Recording of regional electrophysiological information by analysis of surface potentials to give a complete picture of the effects of the currents from the heart on the body surface. It has been applied to the diagnosis of old inferior myocardial infarction, localization of the bypass pathway in Wolff-Parkinson-White syndrome, recognition of ventricular hypertrophy, estimation of the size of a myocardial infarct, and the effects of different interventions designed to reduce infarct size. The limiting factor at present is the complexity of the recording and analysis, which requires 100 or more electrodes, sophisticated instrumentation, and dedicated personnel. (Braunwald, Heart Disease, 4th ed)beta-Alanine: An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Pacemaker, Artificial: A device designed to stimulate, by electric impulses, contraction of the heart muscles. It may be temporary (external) or permanent (internal or internal-external).Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Atrioventricular Node: A small nodular mass of specialized muscle fibers located in the interatrial septum near the opening of the coronary sinus. It gives rise to the atrioventricular bundle of the conduction system of the heart.Sick Sinus Syndrome: A condition caused by dysfunctions related to the SINOATRIAL NODE including impulse generation (CARDIAC SINUS ARREST) and impulse conduction (SINOATRIAL EXIT BLOCK). It is characterized by persistent BRADYCARDIA, chronic ATRIAL FIBRILLATION, and failure to resume sinus rhythm following CARDIOVERSION. This syndrome can be congenital or acquired, particularly after surgical correction for heart defects.Time Factors: Elements of limited time intervals, contributing to particular results or situations.International Normalized Ratio: System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.Embolism: Blocking of a blood vessel by an embolus which can be a blood clot or other undissolved material in the blood stream.Echocardiography, Transesophageal: Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues using a transducer placed in the esophagus.Heart Rate: The number of times the HEART VENTRICLES contract per unit of time, usually per minute.Cryosurgery: The use of freezing as a special surgical technique to destroy or excise tissue.Wolff-Parkinson-White Syndrome: A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.Tachycardia, Ectopic Atrial: Abnormally rapid heartbeats originating from one or more automatic foci (nonsinus pacemakers) in the HEART ATRIUM but away from the SINOATRIAL NODE. Unlike the reentry mechanism, automatic tachycardia speeds up and slows down gradually. The episode is characterized by a HEART RATE between 135 to less than 200 beats per minute and lasting 30 seconds or longer.Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)Hemorrhage: Bleeding or escape of blood from a vessel.Cardiac Surgical Procedures: Surgery performed on the heart.Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)Atrial Function, Right: The hemodynamic and electrophysiological action of the RIGHT ATRIUM.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Risk Assessment: The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)Arrhythmia, Sinus: Irregular HEART RATE caused by abnormal function of the SINOATRIAL NODE. It is characterized by a greater than 10% change between the maximum and the minimum sinus cycle length or 120 milliseconds.Tachycardia, Supraventricular: A generic expression for any tachycardia that originates above the BUNDLE OF HIS.Incidence: The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.Echocardiography: Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Atrial Septum: The thin membrane-like muscular structure separating the right and the left upper chambers (HEART ATRIA) of a heart.Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.Sinoatrial Node: The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).Bradycardia: Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.Defibrillators, Implantable: Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. They consist of an impulse generator, batteries, and electrodes.Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.Mitral Valve: The valve between the left atrium and left ventricle of the heart.Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)Pericardium: A conical fibro-serous sac surrounding the HEART and the roots of the great vessels (AORTA; VENAE CAVAE; PULMONARY ARTERY). Pericardium consists of two sacs: the outer fibrous pericardium and the inner serous pericardium. The latter consists of an outer parietal layer facing the fibrous pericardium, and an inner visceral layer (epicardium) resting next to the heart, and a pericardial cavity between these two layers.Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.Fibrinolytic Agents: Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.Atrial Remodeling: Long-term changes in the electrophysiological parameters and/or anatomical structures of the HEART ATRIA that result from prolonged changes in atrial rate, often associated with ATRIAL FIBRILLATION or long periods of intense EXERCISE.Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.Electrophysiology: The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.Pyridones: Pyridine derivatives with one or more keto groups on the ring.Heart Block: Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects.Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.Models, Cardiovascular: Theoretical representations that simulate the behavior or activity of the cardiovascular system, processes, or phenomena; includes the use of mathematical equations, computers and other electronic equipment.Chi-Square Distribution: A distribution in which a variable is distributed like the sum of the squares of any given independent random variable, each of which has a normal distribution with mean of zero and variance of one. The chi-square test is a statistical test based on comparison of a test statistic to a chi-square distribution. The oldest of these tests are used to detect whether two or more population distributions differ from one another.Adrenergic beta-Antagonists: Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.Comorbidity: The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.Action Potentials: Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli.Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Aprindine: A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.Mitral Valve Stenosis: Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.Coronary Artery Bypass: Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Autonomic Denervation: The removal or interruption of some part of the autonomic nervous system for therapeutic or research purposes.Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Vitamin K: A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.Age Factors: Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.Cardiac Complexes, Premature: A group of cardiac arrhythmias in which the cardiac contractions are not initiated at the SINOATRIAL NODE. They include both atrial and ventricular premature beats, and are also known as extra or ectopic heartbeats. Their frequency is increased in heart diseases.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Rheumatic Heart Disease: Cardiac manifestation of systemic rheumatological conditions, such as RHEUMATIC FEVER. Rheumatic heart disease can involve any part the heart, most often the HEART VALVES and the ENDOCARDIUM.Pulmonary Veno-Occlusive Disease: Pathological process resulting in the fibrous obstruction of the small- and medium-sized PULMONARY VEINS and PULMONARY HYPERTENSION. Veno-occlusion can arise from fibrous proliferation of the VASCULAR INTIMA and VASCULAR MEDIA; THROMBOSIS; or a combination of both.Stroke Volume: The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume.Coronary Sinus: A short vein that collects about two thirds of the venous blood from the MYOCARDIUM and drains into the RIGHT ATRIUM. Coronary sinus, normally located between the LEFT ATRIUM and LEFT VENTRICLE on the posterior surface of the heart, can serve as an anatomical reference for cardiac procedures.Heart Arrest: Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.Proportional Hazards Models: Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.Esophageal Fistula: Abnormal passage communicating with the ESOPHAGUS. The most common type is TRACHEOESOPHAGEAL FISTULA between the esophagus and the TRACHEA.Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.Heart Ventricles: The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation.Signal Processing, Computer-Assisted: Computer-assisted processing of electric, ultrasonic, or electronic signals to interpret function and activity.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.Platelet Aggregation Inhibitors: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.Logistic Models: Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.Epicardial Mapping: Recording the locations and measurements of electrical activity in the EPICARDIUM by placing electrodes on the surface of the heart to analyze the patterns of activation and to locate arrhythmogenic sites.Vena Cava, Superior: The venous trunk which returns blood from the head, neck, upper extremities and chest.Cardiac Catheters: Catheters inserted into various locations within the heart for diagnostic or therapeutic purposes.Pericarditis: Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.Randomized Controlled Trials as Topic: Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.Atrioventricular Block: Impaired impulse conduction from HEART ATRIA to HEART VENTRICLES. AV block can mean delayed or completely blocked impulse conduction.Endocardium: The innermost layer of the heart, comprised of endothelial cells.Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.Fluoroscopy: Production of an image when x-rays strike a fluorescent screen.Digitalis Glycosides: Glycosides from plants of the genus DIGITALIS. Some of these are useful as cardiotonic and anti-arrhythmia agents. Included also are semi-synthetic derivatives of the naturally occurring glycosides. The term has sometimes been used more broadly to include all CARDIAC GLYCOSIDES, but here is restricted to those related to Digitalis.Feasibility Studies: Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.Echocardiography, Doppler: Measurement of intracardiac blood flow using an M-mode and/or two-dimensional (2-D) echocardiogram while simultaneously recording the spectrum of the audible Doppler signal (e.g., velocity, direction, amplitude, intensity, timing) reflected from the moving column of red blood cells.Ablation Techniques: Removal of tissue by vaporization, abrasion, or destruction. Methods used include heating tissue by hot liquids or microwave thermal heating, freezing (CRYOABLATION), chemical ablation, and photoablation with LASERS.Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.Cardiac Catheterization: Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Equipment Design: Methods of creating machines and devices.Hospitalization: The confinement of a patient in a hospital.Bundle of His: Small band of specialized CARDIAC MUSCLE fibers that originates in the ATRIOVENTRICULAR NODE and extends into the membranous part of the interventricular septum. The bundle of His, consisting of the left and the right bundle branches, conducts the electrical impulses to the HEART VENTRICLES in generation of MYOCARDIAL CONTRACTION.Surgery, Computer-Assisted: Surgical procedures conducted with the aid of computers. This is most frequently used in orthopedic and laparoscopic surgery for implant placement and instrument guidance. Image-guided surgery interactively combines prior CT scans or MRI images with real-time video.Cardiac Electrophysiology: The study of the electrical activity and characteristics of the HEART; MYOCARDIUM; and CARDIOMYOCYTES.Registries: The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.Cardiology: The study of the heart, its physiology, and its functions.Heart: The hollow, muscular organ that maintains the circulation of the blood.Thyrotoxicosis: A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Autonomic Nervous System: The ENTERIC NERVOUS SYSTEM; PARASYMPATHETIC NERVOUS SYSTEM; and SYMPATHETIC NERVOUS SYSTEM taken together. Generally speaking, the autonomic nervous system regulates the internal environment during both peaceful activity and physical or emotional stress. Autonomic activity is controlled and integrated by the CENTRAL NERVOUS SYSTEM, especially the HYPOTHALAMUS and the SOLITARY NUCLEUS, which receive information relayed from VISCERAL AFFERENTS.ThiophenesDefibrillators: Cardiac electrical stimulators that apply brief high-voltage electroshocks to the HEART. These stimulators are used to restore normal rhythm and contractile function in hearts of patients who are experiencing VENTRICULAR FIBRILLATION or ventricular tachycardia (TACHYCARDIA, VENTRICULAR) that is not accompanied by a palpable PULSE. Some defibrillators may also be used to correct certain noncritical dysrhythmias (called synchronized defibrillation or CARDIOVERSION), using relatively low-level discharges synchronized to the patient's ECG waveform. (UMDNS, 2003)Luria-Nebraska Neuropsychological Battery: A series of tests designed to assess neuropsychological function. The battery is used to diagnose specific cerebral dysfunction and also to determine lateralization.Intracranial Hemorrhages: Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.Electrophysiological Phenomena: The electrical properties, characteristics of living organisms, and the processes of organisms or their parts that are involved in generating and responding to electrical charges.Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).Vagus Nerve: The 10th cranial nerve. The vagus is a mixed nerve which contains somatic afferents (from skin in back of the ear and the external auditory meatus), visceral afferents (from the pharynx, larynx, thorax, and abdomen), parasympathetic efferents (to the thorax and abdomen), and efferents to striated muscle (of the larynx and pharynx).Mitral Valve Insufficiency: Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.Heart Valve Prosthesis Implantation: Surgical insertion of synthetic material to repair injured or diseased heart valves.Anisoles: A group of compounds that are derivatives of methoxybenzene and contain the general formula R-C7H7O.Electrodes: Electric conductors through which electric currents enter or leave a medium, whether it be an electrolytic solution, solid, molten mass, gas, or vacuum.Ventricular Function, Left: The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance.Antithrombins: Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.Cardiopulmonary Resuscitation: The artificial substitution of heart and lung action as indicated for HEART ARREST resulting from electric shock, DROWNING, respiratory arrest, or other causes. The two major components of cardiopulmonary resuscitation are artificial ventilation (RESPIRATION, ARTIFICIAL) and closed-chest CARDIAC MASSAGE.Intracranial Embolism: Blocking of a blood vessel in the SKULL by an EMBOLUS which can be a blood clot (THROMBUS) or other undissolved material in the blood stream. Most emboli are of cardiac origin and are associated with HEART DISEASES. Other non-cardiac sources of emboli are usually associated with VASCULAR DISEASES.Premedication: Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION.Heart Valves: Flaps of tissue that prevent regurgitation of BLOOD from the HEART VENTRICLES to the HEART ATRIA or from the PULMONARY ARTERIES or AORTA to the ventricles.Voltage-Sensitive Dye Imaging: Optical imaging techniques used for recording patterns of electrical activity in tissues by monitoring transmembrane potentials via FLUORESCENCE imaging with voltage-sensitive fluorescent dyes.Endpoint Determination: Establishment of the level of a quantifiable effect indicative of a biologic process. The evaluation is frequently to detect the degree of toxic or therapeutic effect.Electric Injuries: Injuries caused by electric currents. The concept excludes electric burns (BURNS, ELECTRIC), but includes accidental electrocution and electric shock.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Telemetry: Transmission of the readings of instruments to a remote location by means of wires, radio waves, or other means. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.Practice Guidelines as Topic: Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery.Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.Hemodynamics: The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.Hyperthyroidism: Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.Severity of Illness Index: Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.DenmarkThoracic Surgical Procedures: Surgery performed on the thoracic organs, most commonly the lungs and the heart.Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Vagus Nerve Stimulation: An adjunctive treatment for PARTIAL EPILEPSY and refractory DEPRESSION that delivers electrical impulses to the brain via the VAGUS NERVE. A battery implanted under the skin supplies the energy.Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.Intracranial Embolism and Thrombosis: Embolism or thrombosis involving blood vessels which supply intracranial structures. Emboli may originate from extracranial or intracranial sources. Thrombosis may occur in arterial or venous structures.Myocardium: The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.Goats: Any of numerous agile, hollow-horned RUMINANTS of the genus Capra, in the family Bovidae, closely related to the SHEEP.

Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. (1/5583)

BACKGROUND: We correlated the electrophysiologic (EP) effects of adenosine with tachycardia mechanisms in patients with supraventricular tachycardias (SVT). METHODS AND RESULTS: Adenosine was administered to 229 patients with SVTs during EP study: atrioventricular (AV) reentry (AVRT; n=59), typical atrioventricular node reentry (AVNRT; n=82), atypical AVNRT (n=13), permanent junctional reciprocating tachycardia (PJRT; n=12), atrial tachycardia (AT; n=53), and inappropriate sinus tachycardia (IST; n=10). There was no difference in incidence of tachycardia termination at the AV node in AVRT (85%) versus AVNRT (86%) after adenosine, but patients with AVRT showed increases in the ventriculoatrial (VA) intervals (13%) compared with typical AVNRT (0%), P<0.005. Changes in atrial, AV, or VA intervals after adenosine did not predict the mode of termination of long R-P tachycardias. For patients with AT, there was no correlation with location of the atrial focus and adenosine response. AV block after adenosine was only observed in AT patients (27%) or IST (30%). Patients with IST showed atrial cycle length increases after adenosine (P<0.05) with little change in activation sequence. The incidence of atrial fibrillation after adenosine was higher for those with AVRT (15%) compared with typical AVNRT (0%) P<0.001, or atypical AVNRT (0%) but similar to those with AT (11%) and PJRT (17%). CONCLUSIONS: The EP response to adenosine proved of limited value to identify the location of AT or SVT mechanisms. Features favoring AT were the presence of AV block or marked shortening of atrial cycle length before tachycardia suppression. Atrial fibrillation was more common after adenosine in patients with AVRT, PJRT, or AT. Patients with IST showed increases in cycle length with little change in atrial activation sequence after adenosine.  (+info)

Regional differences in the recovery course of tachycardia-induced changes of atrial electrophysiological properties. (2/5583)

BACKGROUND: Regional differences in recovery of tachycardia-induced changes of atrial electrophysiological properties have not been well studied. METHODS AND RESULTS: In the control group (5 dogs), atrial effective refractory period (AERP) and inducibility of atrial fibrillation (AF) were assessed before and every 4 hours for 48 hours after complete atrioventricular junction (AVJ) ablation with 8-week VVI pacing. In experimental group 1 (15 dogs), AERP and inducibility of AF were assessed before and after complete AVJ ablation with 8-week rapid right atrial (RA) pacing (780 bpm) and VVI pacing. In experimental group 2 (7 dogs), AERP and inducibility of AF were assessed before and after 8-week rapid left atrial (LA) pacing and VVI pacing. AERP and inducibility and duration of AF were obtained from 7 epicardial sites. In the control group, atrial electrophysiological properties obtained immediately and during 48-hour measurements after pacing did not show any change. In the 2 experimental groups, recovery of atrial electrophysiological properties included a progressive recovery of AERP shortening, recovery of AERP maladaptation, and decrease of duration and episodes of reinduced AF. However, recovery of shortening and maladaptation of AERP and inducibility of AF was slower at the LA than at the RA and Bachmann's bundle. CONCLUSIONS: The LA had a slower recovery of tachycardia-induced changes of atrial electrophysiological properties, and this might play a critical role in initiation of AF.  (+info)

Effect of 5-HT4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes. (3/5583)

OBJECTIVE: 5-HT4 receptors are present in human atrial cells and their stimulation has been implicated in the genesis of atrial arrhythmias including atrial fibrillation. An I(f)-like current has been recorded in human atrial myocytes, where it is modulated by beta-adrenergic stimulation. In the present study, we investigated the effect of serotonin (5-hydroxytryptamine, 5-HT) on I(f) electrophysiological properties, in order to get an insight into the possible contribution of I(f) to the arrhythmogenic action of 5-HT in human atria. METHODS: Human atrial myocytes were isolated by enzymatic digestion from samples of atrial appendage of patients undergoing coeffective cardiac surgery. Patch-clamped cells were superfused with a modified Tyrode's solution in order to amplify I(f) and reduce overlapping currents. RESULTS AND CONCLUSIONS: A time-dependent, cesium-sensitive increasing inward current, that we had previously described having the electrophysiological properties of the pacemaker current I(f), was elicited by negative steps (-60 to -130 mV) from a holding potential of -40 mV. Boltzmann fit of control activation curves gave a midpoint (V1/2) of -88.9 +/- 2.6 mV (n = 14). 5-HT (1 microM) consistently caused a positive shift of V1/2 of 11.0 +/- 2.0 mV (n = 8, p < 0.001) of the activation curve toward less negative potentials, thus increasing the amount of current activated by clamp steps near the physiological maximum diastolic potential of these cells. The effect was dose-dependent, the EC50 being 0.14 microM. Maximum current amplitude was not changed by 5-HT. 5-HT did not increase I(f) amplitude when the current was maximally activated by cAMP perfused into the cell. The selective 5-HT4 antagonists, DAU 6285 (10 microM) and GR 125487 (1 microM), completely prevented the effect of 5-HT on I(f). The shift of V1/2 caused by 1 microM 5-HT in the presence of DAU 6285 or GR 125487 was 0.3 +/- 1 mV (n = 6) and 1.0 +/- 0.6 mV (n = 5), respectively (p < 0.01 versus 5-HT alone). The effect of 5-HT4 receptor blockade was specific, since neither DAU 6285 nor GR 125487 prevented the effect of 1 microM isoprenaline on I(f). Thus, 5-HT4 stimulation increases I(f) in human atrial myocytes; this effect may contribute to the arrhythmogenic action of 5-HT in human atrium.  (+info)

Effects of cycloprotobuxine-A on atrial fibrillation. (4/5583)

AIM: To study the effects of cycloprotobuxine-A (Cyc-A) on atrial fibrillation. METHODS: Atrial fibrillations in vivo and in vitro were induced by arrhythmogenic drugs. Action potentials were measured by the standard microelectrode technique. RESULTS: Cyc-A, similar to or slightly stronger than amiodarone (Ami), decreased incidences of atrial fibrillation elicited by CaCl2-acetylcholine in mice and increased doses of aconitine, ouabain, or adrenaline to elicit atrial fibrillation in isolated guinea pig atria. Cyc-A 0.3-100 mumol.L-1 decreased the normal automaticity and 0.3-30 mumol.L-1 attenuated or almost abolished the isoprenaline-induced abnormal increase in automaticity in sinus nodal cells. In isolated left atria, Cyc-A 0.3-30 mumol.L-1 inhibited the abnormal rhythmic activity elicited by adrenaline, prolonged action potential duration (APD) and effective refractory period, and reduced excitability. At 3-30 mumol.L-1, Cyc-A also decreased the maximal velocity of depolarization (Vmax). Cyc-A antagonized the acetylcholine-induced shortening of APD. These electrophysiologic effects were similar to those of amiodarone, but Ami did not affect the Vmax. CONCLUSION: Cyc-A produces a protective effect against experimental atrial fibrillation via a prolongation of repolarization, a decease of automaticity, and an inhibition of excitability.  (+info)

Atrioventricular nodal ablation and implantation of mode switching dual chamber pacemakers: effective treatment for drug refractory paroxysmal atrial fibrillation. (5/5583)

OBJECTIVE: To assess the effect of atrioventricular node ablation and implantation of a dual chamber, mode switching pacemaker on quality of life, exercise capacity, and left ventricular systolic function in patients with drug refractory paroxysmal atrial fibrillation. PATIENTS: 18 consecutive patients with drug refractory paroxysmal atrial fibrillation. METHODS: Quality of life was assessed before and after the procedure using the psychological general wellbeing index (PGWB), the McMaster health index (MHI), and a visual analogue scale for cardiac symptoms. Nine of the patients also underwent symptom limited exercise tests and echocardiography to assess left ventricular systolic function. RESULTS: The procedure allowed a reduction in antiarrhythmic drug treatment (p < 0.01). PGWB and symptom scores improved (p < 0.01) but the MHI score did not change. Left ventricular systolic function and exercise capacity were unchanged. CONCLUSIONS: Atrioventricular node ablation and implantation of a DDDR/MS pacemaker is effective treatment for refractory paroxysmal atrial fibrillation, producing improved quality of life while allowing a reduction in drug burden. The popularity of the treatment is justified, but further studies are needed to determine optimum timing of intervention.  (+info)

Predictors of atrial rhythm after atrioventricular node ablation for the treatment of paroxysmal atrial arrhythmias. (6/5583)

OBJECTIVE: To assess the natural history of the atrial rhythm of patients with paroxysmal atrial arrhythmias undergoing atrioventricular node ablation and permanent pacemaker implantation. DESIGN AND SETTING: A retrospective cohort study of consecutive patients identified from the pacemaker database and electrophysiology records of a tertiary referral hospital. PATIENTS: 62 consecutive patients with paroxysmal atrial arrhythmias undergoing atrioventricular node ablation and permanent pacemaker implantation between 1988 and July 1996. MAIN OUTCOME MEASURES: (1) Atrial rhythm on final follow up ECG, classified as either ordered (sinus rhythm or atrial pacing) or disordered (atrial fibrillation, atrial flutter or atrial tachycardia). (2) Chronic atrial fibrillation, defined as a disordered rhythm on two consecutive ECGs (or throughout a 24 hour Holter recording) with no ordered rhythm subsequently documented. RESULTS: Survival analysis showed that 75% of patients progressed to chronic atrial fibrillation by 2584 days (86 months). On multiple logistic regression analysis a history of electrical cardioversion, increasing patient age, and VVI pacing were associated with the development of chronic atrial fibrillation. A history of electrical cardioversion and increasing patient age were associated with a disordered atrial rhythm on the final follow up ECG. CONCLUSIONS: Patients with paroxysmal atrial arrhythmias are at high risk of developing chronic atrial fibrillation. A history of direct current cardioversion.  (+info)

Differential effects of defibrillation on systemic and cardiac sympathetic activity. (7/5583)

OBJECTIVE: To assess the effect of defibrillation shocks on cardiac and circulating catecholamines. DESIGN: Prospective examination of myocardial catecholamine balance during dc shock by simultaneous determination of arterial and coronary sinus plasma concentrations. Internal countershocks (10-34 J) were applied in 30 patients after initiation of ventricular fibrillation for a routine implantable cardioverter defibrillator test. Another 10 patients were externally cardioverted (50-360 J) for atrial fibrillation. MAIN OUTCOME MEASURES: Transcardiac noradrenaline, adrenaline, and lactate gradients immediately after the shock. RESULTS: After internal shock, arterial noradrenaline increased from a mean (SD) of 263 (128) pg/ml at baseline to 370 (148) pg/ml (p = 0.001), while coronary sinus noradrenaline fell from 448 (292) to 363 (216) pg/ml (p = 0.01), reflecting a shift from cardiac net release to net uptake. After external shock delivery, there was a similar increase in arterial noradrenaline, from 260 (112) to 459 (200) pg/ml (p = 0.03), while coronary sinus noradrenaline remained unchanged. Systemic adrenaline increased 11-fold after external shock (p = 0.01), outlasting the threefold rise following internal shock (p = 0.001). In both groups, a negative transmyocardial adrenaline gradient at baseline decreased further, indicating enhanced myocardial uptake. Cardiac lactate production occurred after ventricular fibrillation and internal shock, but not after external cardioversion, so the neurohumoral changes resulted from the defibrillation process and not from alterations in oxidative metabolism. CONCLUSIONS: A dc shock induces marked systemic sympathoadrenal and sympathoneuronal activation, but attenuates cardiac sympathetic activity. This might promote the transient myocardial depression observed after electrical discharge to the heart.  (+info)

Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. (8/5583)

OBJECTIVE: To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients. DESIGN: Double blind, randomised study. SETTING: 43 European hospitals. PATIENTS: 308 patients (mean age 60 years, 70% men, 48% with heart disease) with sustained atrial fibrillation (n = 251) or atrial flutter (n = 57) (duration three hours to 45 days) were randomised to three groups to receive a 10 minute infusion of 1 mg ibutilide (n = 99), 2 mg ibutilide (n = 106), or 1.5 mg/kg DL-sotalol (n = 103). Infusion was discontinued at termination of the arrhythmia. MAIN OUTCOME MEASURE: Successful conversion of atrial fibrillation or flutter, defined as termination of arrhythmia within one hour of treatment. RESULTS: Both drugs were more effective against atrial flutter than against atrial fibrillation. Ibutilide was superior to DL-sotalol for treating atrial flutter (70% and 56% v 19%), while the high dose of ibutilide was more effective for treating atrial fibrillation than DL-sotalol (44% v 11%) and the lower dose of ibutilide (44% v 20%, p < 0.01). The mean (SD) time to arrhythmia termination was 13 (7) minutes with 2 mg ibutilide, 19 (15) minutes with 1 mg ibutilide, and 25 (17) minutes with DL-sotalol. In all patients, the duration of arrhythmia before treatment was a predictor of arrhythmia termination, although this was less obvious in the group that received 2 mg ibutilide. This dose converted almost 48% of atrial fibrillation that was present for more than 30 days. Concomitant use of digitalis or nifedipine and prolongation of the QTc interval were not predictive of arrhythmia termination. Bradycardia (6.5%) and hypotension (3.7%) were more common side effects with DL-sotalol. Of 211 patients given ibutilide, two (0.9%) who received the higher dose developed polymorphic ventricular tachycardia, one of whom required direct current cardioversion. CONCLUSION: Ibutilide (given in 1 or 2 mg doses over 10 minutes) is highly effective for rapidly terminating persistent atrial fibrillation or atrial flutter. This new class III drug, under monitored conditions, is a potential alternative to currently available cardioversion options.  (+info)

*Familial atrial fibrillation

Atrial fibrillation also increases the risk of stroke. Complications of familial atrial fibrillation can occur at any age, ... The KCNE2 and KCNJ2 genes are associated with familial atrial fibrillation. A small percentage of all cases of familial atrial ... Researchers are working to determine which genetic changes may influence the risk of atrial fibrillation. Familial atrial ... Most cases of atrial fibrillation are not caused by mutations in a single gene. This condition is often related to structural ...

*Atrial Fibrillation Association

"Atrial fibrillation - pulse checks on the NHS". Glyn Davies MP. Retrieved 4 June 2013. Official website NHS Choices guidance on ... The aim of the charter is to turn the world's attention to atrial fibrillation and AF-related stroke. Stop Start Campaign - ... In 2011 an All-Party Parliamentary Group on atrial fibrillation (APGAF) was established in partnership with the AF Association ... Sign Against Stroke - Patient organisations from twenty countries produced the Global Atrial Fibrillation Charter. Launched at ...

*Management of atrial fibrillation

Stroke Risk in Atrial Fibrillation Working Group (2007). "Independent predictors of stroke in patients with atrial fibrillation ... Oct 2010). "Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of ... 2006). "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel ... fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III ...

*AZD1305

... in atrial myocytes, which aids in suppressing atrial fibrillation. AF and TdP may be induced with L-type calcium channel ... "AZD1305 Exerts Atrial Predominant Electrophysiological Actions and is Effective in Suppressing Atrial Fibrillation and ... Atrial fibrillation (AF) is a form of cardiac arrhythmia that arises with disorganized and rapid action potentials conducted ... specifically atrial fibrillation and flutter. In vitro studies have shown that this combined-ion channel blocker inhibits ...

*List of OMIM disorder codes

TF Atrial fibrillation; 608583; GJA5 Atrial fibrillation, familial, 3; 607554; KCNQ1 Atrial fibrillation, familial, 4; 611493; ... KCNE2 Atrial fibrillation, familial, 6; 612201; NPPA Atrial fibrillation, familial, 7; 612240; KCNA5 Atrial septal defect 4; ... 611363; TBX20 Atrial septal defect 5; 612794; ACTC1 Atrial septal defect 6; 613087; TLL1 Atrial septal defect with ... TEK Ventricular fibrillation, familial, 1; 603829; SCN5A Ventricular fibrillation, paroxysmal familial, 2; 612956; DPP6 ...

*Pump thrombosis

Examples: Atrial fibrillation; Infection. 1. Implantation technique. Example: Inflow cannula malposition. 2. Inadequate ...

*Timeline of cardiovascular disease

"Atrial Fibrillation Association". Retrieved 31 July 2016. "Deaths due to cardiovascular disease". Retrieved 1 July 2016. "Sleep ...

*Ashman phenomenon

Harrigan, RA; Garg, M (Dec 2013). "An interesting cause of wide complex tachycardia: Ashman's phenomenon in atrial fibrillation ... often seen isolated that is typically seen in atrial fibrillation. It is more often misinterpreted as a premature ventricular ... Gouaux, JL; Ashman, R (Sep 1947). "Auricular fibrillation with aberration simulating ventricular paroxysmal tachycardia". ...

*Heart Rhythm Society

"Atrial Fibrillation Awareness Campaign". Heart Rhythm Society. Retrieved 23 January 2013. "September is Atrial Fibrillation ... The Heart Rhythm Society (HRS), through its efforts during Atrial Fibrillation Awareness (AFib) Month in September and ...

*Left atrial enlargement

"Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade ... "Atrial enlargement as a consequence of atrial fibrillation A prospective echocardiographic study". Circulation. 82 (3): 792-7. ... However, if atrial fibrillation is present, a P wave would not be present. In any case, LAE can be diagnosed and measured using ... Also, a study found that LAE can occur as a consequence of atrial fibrillation (AF), although another study found that AF by ...

*James Mackenzie (cardiologist)

He had his first heart attack in 1901, and recorded in himself the atrial fibrillation that accompanied this episode. By 1907 ... McMichael J. (July 1981). "Sir James Mackenzie and atrial fibrillation-a new perspective". J R Coll Gen Pract. 31 (228): 402-6 ... Fazekas, T; Liszkai, G; Bielik, H; Lüderitz, B (2003). "[History of atrial fibrillation]". Zeitschrift für Kardiologie. 92 (2 ... Fazekas, Tamás; Liszkai, Gizella (2002). "[History of atrial fibrillation]". Orvosi hetilap. 143 (6) (published Feb 10, 2002). ...

*Bisphosphonate

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (April 2008). "Use of alendronate and risk of incident atrial fibrillation ... Cummings SR, Schwartz AV, Black DM (May 2007). "Alendronate and atrial fibrillation". N. Engl. J. Med. 356 (18): 1895-6. doi: ... although care must be taken in certain populations at high risk of serious adverse effects from atrial fibrillation (such as ... as a risk factor for atrial fibrillation in women. The inflammatory response to bisphosphonates or fluctuations in calcium ...

*Steroid use in American football

Sullivan ML, Martinez CM, Gallagher EJ (1999). "Atrial fibrillation and anabolic steroids". The Journal of emergency medicine. ...

*Betrixaban

Sobieraj-Teague, M.; O'donnell, M.; Eikelboom, J. (2009). "New Anticoagulants for Atrial Fibrillation". Seminars in Thrombosis ... "Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation". Current Opinion in Cardiology. 25 (4): 312-20. ... and prevention of stroke following atrial fibrillation, with promising results. Betrixaban is currently being studied in a ...

*Evgeny Pokushalov

"Botox Prevents Atrial Fibrillation: Study". Newsmax.com. Retrieved 2016-08-27. Johnson, Kate. "Can Botulinum Toxin Suppress ...

*Ectopic pacemaker

Abbott, Louise (December 2012). "Atrial Fibrillation- information, symptoms and treatment". Bupa. Cardiac ectopy Clinical ... An ectopic pacemaker located in the atria is known as an atrial pacemaker and can cause the atrial contraction to be faster. An ... and role of segmental superior vena cava isolation in the treatment of atrial fibrillation". Journal of Electrocardiology. 40 ( ... "Disturbances in Atrial Rhythm and Conduction Following the Surgical Creation of an Atrial Septal Defect by the Blalock-Hanlon ...

*Cox maze procedure

The Cox maze procedure, also known as maze procedure, is a type of heart surgery for atrial fibrillation. "Maze" refers to the ... cardiac surgery procedure intended to eliminate atrial fibrillation (AF). The first such procedure was performed by Dr. Cox at ... "The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure". J Thorac Cardiovasc Surg. ... "The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant ...

*Menarini

"Ranolazine Reduces The Late Recurrences Of Atrial Fibrillation. An Exploratory Analysis Of The Raffaello Study". Treatment of ... pharmacological-atrial fibrillation. 130. November 2014. Retrieved 2016-11-07. "MEN1112, a Novel Humanized De-Fucosylated ...

*Cardiology

... atrial fibrillation affects about 2% to 3% of the population. Atrial fibrillation and atrial flutter resulted in 112,000 deaths ... Supraventricular tachycardias include atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia. ... Zoni-Berisso, M; Lercari, F; Carazza, T; Domenicucci, S (2014). "Epidemiology of atrial fibrillation: European perspective". ... as atrial fibrillation) and others are common and are a major cause of mortality in elderly people. Vascular disorders such as ...

*Peter R. Kowey

doi.org/10.1161/CIRCULATIONAHA.116.026693 "Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac ... "Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration." Freedman B, Camm J, Calkins H… Kowey ... "Clinical Management of Atrial Fibrillation" (2015); and "Cardiac Arrhythmias, Pacing and Sudden Death" (2017). He is a fellow ... a group of 60 heart care experts who drafted a report advocating for markedly increased screenings for atrial fibrillation (AF ...

*Direct Xa inhibitor

Those trials demonstrated efficacy and safety against warfarin for stroke prevention in atrial fibrillation and against low- ... Turpie, AG (Jan 2008). "New oral anticoagulants in atrial fibrillation". European Heart Journal. 29 (2): 155-65. doi:10.1093/ ... their potential to overuse in low risk atrial fibrillation people, their short half live affecting efficacy and their higher ...

*Budiodarone

... in patients with paroxysmal atrial fibrillation and pacemakers with atrial fibrillation data logging capabilities [abstract]. ... Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342:913-920 Singh, B.N., et al. Amiodarone versus ... A decrease in heart rate reduces the risk of atrial fibrillation. Preliminary trials of budiodarone have administered the drug ... Evidence has shown that 400-600 mg bid doses were associated with the highest reduction in atrial fibrillation burden (54.4% ...

*KCNE1

... is associated with altered predisposition to lone atrial fibrillation and postoperative atrial fibrillation. Atrial KCNE1 ... Han HG, Wang HS, Yin Z, Jiang H, Fang M, Han J (20 October 2014). "KCNE1 112G>a polymorphism and atrial fibrillation risk: a ... "Atrial fibrillation in KCNE1-null mice". Circulation Research. 97 (1): 62-9. doi:10.1161/01.RES.0000173047.42236.88. PMID ... gain-of-function KCNE1 mutations are associated with early-onset atrial fibrillation. A common KCNE1 polymorphism, S38G, ...

*Edoxaban

... in patients with nonvalvular atrial fibrillation (NVAF) Edoxaban is contraindicated in nonvalvular atrial fibrillation (NVAF) ... United States of America: McGraw-Hill, 2009 Turpie AG (January 2008). "New oral anticoagulants in atrial fibrillation". ...

*Nicholas Kounis

1975; 231: 734-5. Micturition syncope, hypokalemia, and atrial fibrillation. Kounis NG, Kenmure AC. JAMA 1976; 236: 954 " ...

*Atrioventricular node

... such as atrial fibrillation or atrial flutter. The AV node's normal intrinsic firing rate without stimulation (such as that ... October 2001). "ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation" (PDF). Journal of the American ... This is the property of the AV node that prevents rapid conduction to the ventricle in cases of rapid atrial rhythms, ... It occurs when the atrial depolarization fail to reach the ventricles or is conducted with an abnormally long delay. It can ...
Atrial fibrillation is the most common arrhythmia and accounts for one-third of hospitalizations for rhythm disorders in the United States. The prevalence of atrial fibrillation averages 1% and increases with age. With the aging of the population, the number of patients with atrial fibrillation is expected to increase 150% by 2050, with more than 50% of atrial fibrillation patients being over the age of 80. This increasing burden of atrial fibrillation will lead to a higher incidence of stroke, as patients with atrial fibrillation have a five- to sevenfold greater risk of stroke than the general population. Strokes secondary to atrial fibrillation have a worse prognosis than in patients without atrial fibrillation. Vitamin K antagonists (e.g., warfarin), direct thrombin inhibitors (dabigatran), and factor Xa inhibitors (rivaroxaban and apixaban) are all oral anticoagulants that have been FDA approved for the prevention of stroke in atrial fibrillation. This review will summarize the
Preface, vii List of contributors, ix. VeniceChart task force composition, xxxiii. List of abbreviations, xxxvii. 1 Anatomy of structures relevant to atrial fibrillation ablation, 1. 2 Pathophysiology of atrial fibrillation, 20. 3 Techniques and technologies for atrial fibrillation catheter ablation, 35. 4 Endpoints of catheter ablation for atrial fibrillation, 61. 5 Patient management pre-, during-, and postablation, 70. 6 Periprocedural and long-term anticoagulation, 77. 7 Periprocedural and late complications, 85. 8 Short- and long-term efficacy of catheter ablation procedures for atrial fibrillation, 118. 9 Indications to atrial fibrillation ablation and cost-effectiveness, 127. 10 Clinical trials on atrial fibrillation/future perspectives, 137. 11 Surgical approach/ablation, 161. 12 Hospital equipment and facilities, personnel, training requirements, and competences, 176. Index, 184. ...
I review the present understanding of thromboembolic complications and their prevention in patients with nonrheumatic atrial fibrillation. Chronic atrial fibrillation carries an annual 3-6% risk of thromboembolic complications, which is 5-7 times greater than that of controls with sinus rhythm. Paroxysmal atrial fibrillation is associated with a lower risk of thromboembolic complications than chronic atrial fibrillation. Heart failure and systemic hypertension seem to be significant clinical risk factors for stroke in patients with atrial fibrillation, but disagreement persists, and, with few exceptions, subgroups at particular risk have not been convincingly identified. The risk of stroke in persons with thyrotoxic atrial fibrillation seems to be lower than believed previously. Clinical studies have shown that left atrial dilatation is a consequence of the duration of atrial fibrillation rather than a cause, but the relation of left atrial enlargement to stroke is uncertain. Cerebral blood flow ...
Atrial fibrillation is a common cause of stroke and other morbidity. Adequate treatment with anticoagulants reduces the risk of stroke by 60 %. Early detection and treatment of atrial fibrillation could prevent strokes. Atrial fibrillation is often asymptomatic and/or paroxysmal. Case-finding with pulse palpation is an effective screening method, but new methods for detecting atrial fibrillation have been developed. To detect paroxysmal atrial fibrillation ambulatory rhythm recording is needed. This study aims to determine the yield of case-finding for atrial fibrillation in primary care patients. In addition, it will determine the diagnostic accuracy of three different case-finding methods. In a multicenter cluster randomised controlled trial, we compare an enhanced protocol for case-finding of atrial fibrillation with usual care. We recruit 96 practices. We include primary care patients aged 65 years or older not diagnosed with atrial fibrillation. Within each practice, a cluster of 200 patients is
Most current treatment guidelines recommend warfarin therapy for patients with atrial fibrillation who are older than 60 years.24 25 In our study only 11% of patients did not have at least one additional vascular risk factor beyond atrial fibrillation and age. This means that most of our patients were at moderate to high risk for stroke.21 This finding is similar to the Cardiovascular Health Study, in which only 8% of patients with atrial fibrillation older than 65 years did not have evidence of cardiovascular disease,39 and the pooled data from the atrial fibrillation trials, in which 15% of patients had no vascular risk factors other than atrial fibrillation.21 Our primary analysis was based on those at moderate to high risk for stroke. Among these patients, there is little controversy among consensus statements and guidelines.14 25 40 Our principal finding is that 60% of patients with atrial fibrillation who are good candidates for anticoagulation (atrial fibrillation plus at least one other ...
Newly diagnosed Atrial Fibrillation patients have many questions about living with A-Fib. These are answers to the most frequently asked questions by patients and their families. (Click on the question to jump to the answer). 1. Cause: "Did I cause my Atrial Fibrillation? Am I responsible for getting A-Fib?". 2. Severity: "My doctor says I had an attack of Atrial Fibrillation. How much trouble am I in?". Related Question: "Is Atrial Fibrillation a prelude to a heart attack?". Related Question: "Can I die from my Atrial Fibrillation? Is it life threatening?". 3. Anomaly? "Could my Atrial Fibrillation go away on its own? I dont want to take any medication. Can I just wait and see?". Related Question: "Is it possible to have a single Atrial Fibrillation attack and not have any others? I had a single episode of A-Fib and was successfully converted in the ER with meds.". Related Question: "How can I tell when Im in A-Fib or just having something like indigestion?". 4. Sex/Exercise: "Should I cool ...
Previous data on spontaneous conversion of atrial fibrillation to sinus rhythm have been derived from smaller series that focused on the utility of specific AV node blocking agents or antiarrhythmic medications for promoting cardioversion. With the possible exception of sotalol, agents such as digoxin, beta-adrenergic receptor antagonists or calcium channel blockers are effective for ventricular rate control but ineffective for converting atrial fibrillation to sinus rhythm [20-25]. Previously, Falk and colleagues [8], examining the efficacy of digoxin for converting atrial fibrillation in a study of 36 patients, reported that 44% of the patients in the placebo arm had spontaneous conversion, compared with 50% of patients randomized to digoxin. Similar results were recently reported by the Digitalis in Acute Atrial Fibrillation (DAAF) investigators [12]. In that multicenter prospective study of digoxin versus placebo for conversion of recent atrial fibrillation, there was no significant ...
Introduction Catheter ablation (CA) for atrial fibrillation (AF) is growing exponentially. Although ablation for paroxysmal AF (PAF) is associated with shorter procedure times and less extensive left atrial ablation vs persistent AF thromboembolic complications can occur in both sub-groups. Inadequate anticoagulation leads to thrombotic complications and excessive anticoagulation can lead to bleeding risks. Many centres adopt a policy of discontinuing warfarin in the immediate run-up to the procedure, covering the procedure with unfractionated heparin and "bridging" postoperative patients with low molecular weight heparins (LMWH) back onto warfarin. We wished to determine the safety of CA for AF with a therapeutic INR using both the single transseptal approach and duty cycled radiofrequency energy (RF) with non irrigated PVAC catheters and the double transseptal puncture technique using irrigated RF catheters and either CARTO or NAVX electroanatomical mapping. ...
Atrial Fibrillation patients often have loads of "Why?" and "How?" questions. Here are answers to the most frequently asked questions by patients and their families. (Click on the question to jump to the answer.). 1. Causes: "Why does so much Atrial Fibrillation come from the Pulmonary Vein openings?". Related Question: "Why do older people get Atrial Fibrillation more than younger people?". Related Question: "What causes Paroxysmal A-Fib to turn into Persistent (Chronic) A-Fib?". Related Question: "A-Fib and Flutter-I have both. Does one cause the other?". 2. Hereditary: "Is my Atrial Fibrillation genetic? Will my children get A-Fib too?". 3. PSVT: "Is Atrial Fibrillation (A-Fib) different from what doctors call Paroxysmal Supraventricular Tachycardia?". 4. Adrenergic/Vagal: "What is the difference between "Adrenergic" and "Vagal" Atrial Fibrillation? How can I tell if I have one or the other? Does it really matter? Does Pulmonary Vein Ablation (Isolation) work for Adrenergic and/or Vagal ...
The current study is, to the best of our knowledge, the first to assess the association between the whole spectrum of thyroid disease and the subsequent risk of atrial fibrillation in a population of primary care patients. Our main finding was an apparent linear relation between levels of thyroid dysfunction and atrial fibrillation risk-that is, a low atrial fibrillation risk in hypothyroid patients, a high risk in hyperthyroidism, and a TSH level dependent (a dose-response relation) increased risk of atrial fibrillation in all levels of hyperthyroid disease, even in high normal euthyroid subjects. Notably, in subjects with reduced serum TSH levels but normal free thyroid hormone levels the risk of developing atrial fibrillation was increased approximately 10% in individuals with high normal thyroid function and increased about 40% in those with subclinical hyperthyroidism with suppressed TSH levels (table 4⇑, fig 3⇑). Overall, the relative risk of atrial fibrillation associated with thyroid ...
article{3aabedf9-a573-45ce-ab4a-dcc4e7a6b467, abstract = {,p,Background Electrical cardioversion of atrial fibrillation is associated with an increased risk of embolic stroke, but is generally considered safe if performed within 48 h after onset. Our objective was to investigate if thromboembolism and bleeding in association with cardioversion of atrial fibrillation differed between patients with and without oral anticoagulation. Methods Retrospective study of patients with atrial fibrillation undergoing electrical cardioversion from national Swedish health registries from January 1st 2006 until December 1st 2010. Main outcome measures were thromboembolism and bleeding. Results In total 22,874 atrial fibrillation patients underwent electrical cardioversion, 10,722 with and 12,152 without oral anticoagulation pre-treatment. Patients with low stroke risk (CHA,sub,2,/sub,DS,sub,2,/sub,-VASc 0-1) did not suffer from any thromboembolic complications within 30 days after cardioversion. After ...
Researchers at Western University hope their systematic review of almost 12,000 patients will raise awareness among physicians about the need for more extensive testing for atrial fibrillation, or heart rhythm disturbances, following a stroke or transient ischemic attack (TIA).. The review, published by Lancet Neurology, analyzed the results of 50 studies from four continents and showed that almost 24 per cent of stroke patients with no history of atrial fibrillation can be newly diagnosed with atrial fibrillation when using multiple cardiac monitoring methods sequentially. Thats more than twice higher than previous estimates which are based on only one or two methods of diagnosis.. "We found that by using a sequential combination of different cardiac monitoring methods, the number of ischemic stroke and TIA patients newly diagnosed with atrial fibrillation can be increased considerably," said Dr. Luciano Sposato, a recently recruited Associate Professor of Neurology at Westerns Schulich ...
Atrial fibrillation is a condition in which the hearts upper chambers, the atria, contract at an abnormally rapid rate. It is a common type of arrhythmia, and occurs in 1-2% of the general population. The prevalence of atrial fibrillation increases with age. Between 50 and 70% of patients with atrial fibrillation lasting ,48 hours spontaneously convert to normal sinus rhythm, and drug therapy increases the likelihood of conversion to sinus rhythm. Another treatment option for conversion of atrial fibrillation and atrial flutter is electrical conversion. This is an effective treatment but requires anesthesia.. Current treatment strategy for medical conversion of atrial fibrillation and atrial flutter is to employ drugs that affect ion channel activity in atrial cardiomyocytes. However, such converting drugs all have potentially serious side effects and are expensive. Potassium, sodium, calcium, and magnesium molecules are the most important ions causing electric current in the heart tissue. Our ...
Definition: Patients with persistent atrial fibrillation will be enrolled in this trial. All patients will be required to be in atrial fibrillation on the day of the procedure. Standard pulmonary vein (PV) isolation will be performed. Patients will be enrolled in the trial if they remain in atrial fibrillation after bi-directional block is obtained in the left and right sided PVs. At this point, patients will be randomized to receive 0.25mg of IV ibutilide or a placebo (normal saline). Patients will then undergo additional ablation with areas of complex fractionate electrograms (CFE) being targeted. The duration of additional CFE ablation and use of additional non-PV ablation (i.e. placement of linear lesions) will be left to the discretion of the operator. Patients will be followed for 1 year. The primary outcome assessed will be freedom from AF at 1 year ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Atrial Fibrillation Therapeutics market report covers research informatics related to Atrial Fibrillation Therapeutics clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Atrial Fibrillation Therapeutics clinical trials and for research professionals.. The report, "Atrial Fibrillation Therapeutics Global Clinical Trials Review, H2, 2016″ provides an overview of Atrial Fibrillation Therapeutics clinical trials scenario. This report provides top line data relating to the clinical trials on Atrial Fibrillation Therapeutics. Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor ...
We sought to determine how well PACs predict atrial fibrillation compared to an established but substantially more complex prediction model derived from the Framingham Heart Study," said senior author Gregory Marcus, MD, MAS, an associate professor of medicine who specializes in electrophysiology in the UCSF Division of Cardiology. "Because PACs may themselves have a causal relationship with atrial fibrillation, it is theoretically possible that their eradication, such as through drugs or a catheter ablation procedure, could actually modify atrial fibrillation risk." People who have atrial fibrillation may not show any symptoms, but the condition can increase ones risk of heart failure or stroke. Atrial fibrillation occurs when rapid, random electrical signals cause the atria to contract irregularly and quickly. Marcus and his colleagues studied a random sample of individuals 65 years and older who underwent 24-hour Holter monitoring as part of the national Cardiovascular Health Study from 1989 ...
Aims To test the ability of four circulating biomarkers of fibrosis, and of low left atrial voltage, to predict recurrence of atrial fibrillation after catheter ablation. Background Circulating biomarkers potentially may be used to improve patient selection for atrial fibrillation ablation. Low voltage areas in the left atrium predict arrhythmia recurrence when mapped in sinus rhythm. This study tested type III procollagen N terminal peptide (PIIINP), galectin-3 (gal-3), fibroblast growth factor 23 (FGF-23), and type I collagen C terminal telopeptide (ICTP), and whether low voltage areas in the left atrium predicted atrial fibrillation recurrence, irrespective of the rhythm during mapping. Methods 92 atrial fibrillation ablation patients were studied. Biomarker levels in peripheral and intra-cardiac blood were measured with enzyme-linked immunosorbent assay. Low voltage (,0.5mV) was expressed as a proportion of the mapped left atrial surface area. Follow-up was one year. The primary endpoint was ...
Best Syndication New) - Researchers from the University of California, San Francisco (UCSF) and the Kaiser Permanente Northern California Division of Research, found an increased risk for kidney failure in people who have atrial fibrillation and chronic kidney disease. In general, kidney function can fail over time with the chronic condition which can lead to dialysis treatments or a kidney transplant. Kidney problems are more likely to worsen in atrial fibrillation patients who already have kidney function impairment. The study results were published in the journal Circulation.. Irregular heart rhythm is a very common type of atrial fibrillation. Patients who have atrial fibrillation along with chronic kidney disease or end stage-renal disease (ESRD) are at an increased risk for suffering from a stroke or death. The researchers wanted to understand why atrial fibrillation patients with kidney disease are more likely to have end-stage renal disease compared to those with chronic kidney disease ...
Sophia Antipolis, 10 Oct 2017: Novel smartphone and tablet applications (apps) for atrial fibrillation patients and healthcare professionals have been launched by heart experts. The objectives and design of the apps are outlined in a paper published online today in EP Europace(1), with a summary published in the European Heart Journal (2).. Atrial fibrillation is the most common heart rhythm disorder and significantly increases the risk of stroke and death. One in four middle-aged adults in Europe and the US will develop atrial fibrillation, and the incidence and prevalence are rising.. "Around two-thirds of people in Europe and the US have a mobile device and use it as their main way of accessing online information," said lead author Dr Dipak Kotecha, a clinician scientist in cardiovascular medicine at the Institute of Cardiovascular Sciences, University of Birmingham, UK. "This presents a big opportunity to improve self management and shared decision making in atrial fibrillation.". The My AF ...
A new clinical trial is now underway at the Massachusetts General Hospital to investigate whether combining two endovascular catheter-based procedures will improve the long-term outcome in the treatment of atrial fibrillation, the most common heart rhythm disorder. Mass General is the first hospital in New England - and only the second in the nation - to pair renal artery sympathetic denervation with pulmonary vein isolation (PVI) for patients with atrial fibrillation and hypertension.. "Typically these procedures are done separately," said Moussa Mansour, MD, director of the Atrial Fibrillation Program in the Mass General Institute for Heart, Vascular and Stroke Care. "In this trial, renal denervation is not only performed to treat the patients hypertension, which is the usual goal of the procedure, but as an adjunct to PVI to improve the outcome of atrial fibrillation ablation. We see real potential in this treatment for patients who continue to experience atrial fibrillation symptoms in ...
TY - JOUR. T1 - Stroke prevention in atrial fibrillation. AU - Katsnelson, Michael. AU - Koch, Sebastian. AU - Rundek, Tatjana. PY - 2010/10/1. Y1 - 2010/10/1. N2 - Non-valvular atrial fibrillation is a common and from a neurological perspective the most significant cardiac arrhythmia with a growing world-wide incidence. It also carries a significant associated morbidity and mortality, with cardioembolic strokes arguably being the most disabling sequelae. This brief review will highlight the important studies and the latest treatment modalities available for stroke prevention in patients with non-valvular atrial fibrillation.. AB - Non-valvular atrial fibrillation is a common and from a neurological perspective the most significant cardiac arrhythmia with a growing world-wide incidence. It also carries a significant associated morbidity and mortality, with cardioembolic strokes arguably being the most disabling sequelae. This brief review will highlight the important studies and the latest ...
The data show that there is no survival benefit to the strategy of rhythm control in elderly patients with atrial fibrillation. Indeed there were trends toward higher rates of death and stroke among patients treated with rhythm control. Rate control appears to be an acceptable primary strategy in patients with atrial fibrillation. Long term anticoagulation appears warranted in all patients with risk factors for stroke. Risk factors for ischemic stroke in nonvalvular AF include prior thromboembolism, CHF, HTN, age, DM, female gender, BP greater than 160 mmHg and LV dysfunction. As stated in the ACC/AHA guidelines, maximum protection against ischemic stroke in AF is probably achieved with an international normalized ratio (INR) of 2 to 3, whereas an INR range of 1.6 to 2.5 appears to be associated with incomplete efficacy, estimated at approximately 80% of that achieved with higher intensity anticoagulation. ACC/AHA guidelines recommend that physicians individualize the selection of the ...
Atrial fibrillation is a heterogeneous disorder that is usually characterized by paroxysmal onset, particularly in patients without structural heart disease. Defining biological markers of atrial remodelling would help identify patients at high risk who would benefit most from prophylactic treatment and careful monitoring. Biomarkers of atrial fibrillation progression would be helpful for following patients that present with asymptomatic atrial fibrillation. Notably, the roles of such markers in the pathophysiology of atrial fibrillation must be determined. Some markers may indicate the presence, complications or progression of the disease, while others may be involved in key pathological processes and thus represent novel therapeutic targets. Although a number of markers have been reported as potential predictors of paroxysmal atrial fibrillation progression towards persistent arrhythmia, their usefulness and clinical value need further validation. This report reviews several newly identified markers
Doctors at Washington University School of Medicine in St. Louis are performing a new procedure to treat atrial fibrillation, a common irregular heartbeat.. Available at only a handful of U.S. medical centers, this "hybrid" procedure combines minimally invasive surgical techniques with the latest advances in catheter ablation, a technique that applies scars to the hearts inner surface to block signals causing the heart to misfire. The two-pronged approach gives doctors access to both the inside and outside of the heart at the same time, helping to more completely block the erratic electrical signals that cause atrial fibrillation.. Atrial fibrillation affects more than 2 million Americans, a number that continues to increase as the population ages. While not fatal in itself, patients who suffer from atrial fibrillation are at increased risk of stroke and congestive heart failure. And many, especially those who feel the fibrillations, have shortness of breath, chest pain, fatigue and feelings of ...
The concept that "atrial fibrillation begets atrial fibrillation" might have some important clinical implications. First of all it emphasizes that most of our electrophysiological knowledge stems from acute experiments and that we know relatively little about chronic electrophysiological adaptation processes. If it is true that the long-term shortening of atrial refractoriness during fibrillation is based on a fundamental change in composition of the ion channels responsible for repolarization of the atrial cells, the action of antiarrhythmic drugs on fibrillating atria may be different than the effects as measured during sinus rhythm. The clinically observed diminished efficacy of chemical cardioversion after a prolonged period of atrial fibrillation9 10 11 12 might be explained by such a process of electrical remodeling. In fact it might be imperative to reevaluate the effects of existing anti-fibrillatory drugs in chronically fibrillating hearts. On the other hand it opens the possibility to ...
Our study demonstrates that in dyspneic patients without HF, permanent/paroxysmal AF is associated with increased circulating BNP levels. This pattern was not evident in patients with a final diagnosis of HF. Although the overall diagnostic performance of BNP for HF tended to be lower in patients with AF than in those without, BNP performed well in both groups. Our data also demonstrate that the conventional cutoff value of 100 pg/ml was associated with a markedly lower specificity and positive likelihood ratio in patients with AF than in those without, suggesting that a higher diagnostic threshold should be used to diagnose HF in patients with AF.. The most widely accepted indication for BNP measurement in clinical practice is for the emergency diagnosis of HF in patients presenting with acute dyspnea. The first study suggesting that BNP measurement could prove useful in this setting was published 10 years ago (20). However, clinical use of this test was limited until the publication of the ...
In this paper, R wave peak interval independent atrial fibrillation detection algorithm is proposed based on the analysis of the synchronization feature of the electrocardiogram signal by a deep neural network. Firstly, the synchronization feature of each heartbeat of the electrocardiogram signal is constructed by a Recurrence Complex Network. Then, a convolution neural network is used to detect atrial fibrillation by analyzing the eigenvalues of the Recurrence Complex Network. Finally, a voting algorithm is developed to improve the performance of the beat-wise atrial fibrillation detection. The MIT-BIH atrial fibrillation database is used to evaluate the performance of the proposed method. Experimental results show that the sensitivity, specificity, and accuracy of the algorithm can achieve 94.28%, 94.91%, and 94.59%, respectively. Remarkably, the proposed method was more effective than the traditional algorithms to the problem of individual variation in the atrial fibrillation detection ...
Arterial hypertension (HTN) and atrial fibrillation often coexist and the combination of these two conditions carries an increased risk of stroke. HTN is one of the most important risk factors included in the scores for stoke prediction in atrial fibrillation used to assess the need of anticoagulation, and HTN has also been strictly related to bleeding complications of antithrombotic therapy. Antithrombotic drugs options include vitamin K antagonists, or new oral anticoagulants, recently approved for stroke prevention in nonvalvular atrial fibrillation. More favorable new oral anticoagulant efficacy and safety, compared with warfarin, have been reported in hypertensive patients, making these drugs a first-line choice in this population to prevent cerebrovascular events and reduce the risk of major bleedings. The aim of this review is to explore the relationship among HTN, atrial fibrillation and the risk of stroke and to summarize the evidence on the impact of HTN on the choice of the most ...
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End point reduction in hypertension (LIFE) study Academic Article ...
The most common arrhythmia in older adults is atrial fibrillation, with an estimated prevalence of ≈9% in adults aged ≥80 years and a concomitant increased burden of developing stroke. Additionally, over the past decade, both the incidence and prevalence of atrial fibrillation has markedly increased1 and, with it, the total number of patients potentially requiring long-term oral anticoagulation therapy for the prevention of stroke and systemic embolism. In 2009, the estimated number of atrial fibrillation diagnoses in the United States was 2 643 000, with equal distribution between men and women and 82% at ages ≥65 years, with that number increasing 10% between 1999 to 2005.2 The magnitude of the problem is exemplified by the fact that the risk of stroke in patients with atrial fibrillation increases with age and accounts for ≈45% of embolic strokes, approximately 100 000 annually in the United States.3. Article see p 138. The advent of the novel oral anticoagulants has strikingly ...
Atrial fibrillation is an important and independent risk factor for cerebrovascular disease and vascular dementia. There is increasing evidence that atrial fibrillation is associated with an increased risk of asymptomatic or silent cerebral infarction and as a result may confer an increased risk of progressive cognitive impairment on a person. In this study we sought to determine whether this hypothesis could be explored in a prospective case controlled design. Twenty seven patients with non-valvular atrial fibrillation (NVAF) and no history of stroke, transient ischaemic attack, dementia, and thyrotoxicosis were compared with 54 age and sex matched controls in sinus rhythm. All cases underwent clinical examination, ECG, and psychological assessment using a battery of nine neuropsychological tests. Between group analysis and a comparison of mean test scores of paired controls with cases were undertaken. The presence of atrial fibrillation was consistently associated with poorer performances on ...
Aims To assess the impact of the introduction of direct oral anticoagulants upon the outcomes from elective electrical cardioversion for atrial fibrillation. Methods This is a retrospective comparison of delay to elective cardioversion with different anticoagulants. The data was gathered from a large regional hospital from January 2013 to September 2017. There were 3 measured outcomes: 1) the time in weeks from referral to the date of attempted electrical cardioversion; 2) the proportion of patients who were successfully cardioverted; and 3) the proportion of patients who remained in sinus rhythm by the 12 week follow-up. Time-to-cardioversion was non-parametrically distributed so was analysed with Kruskal-Wallis testing and Mann-Whitney-U testing. Maintenance of sinus rhythm was analysed using z-testing. Results 1,374 patients were submitted to cardioversion. The referrals for cardioversion were either from primary care or from cardiologists. At the time of cardioversion, 789 cases were
A comprehensive research report titled "Global Atrial Fibrillation (Afib) Market (Non-Surgical/Catheter, Surgical- Mini Maze, Hybrid): Analysis By Region, By Country (2016-2021F)" created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, presents the analysis of the global atrial fibrillation or Afib market and has been segmented By Procedures (Surgical Ablation- Mini Maze, Hybrid, Non-Surgical - Catheter); By Region (North America, Europe, APAC, ROW) and By Country (U.S., Canada, UK, Germany, China, Japan).. Market for Afib is growing steadily on account of the rising number of Afib cases, which is caused by the lifestyle related diseases, such as hypertension, diabetes, obesity, and is gaining prominence among both adult and aged population. Rising cases of atrial fibrillation (Afib) among the population along with the growing focus on catheter ablation procedures has led to the growth of atrial fibrillation market.. Among the ...
A comprehensive research report titled "Global Atrial Fibrillation (Afib) Market (Non-Surgical/Catheter, Surgical- Mini Maze, Hybrid): Analysis By Region, By Country (2016-2021F)" created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, presents the analysis of the global atrial fibrillation or Afib market and has been segmented By Procedures (Surgical Ablation- Mini Maze, Hybrid, Non-Surgical - Catheter); By Region (North America, Europe, APAC, ROW) and By Country (U.S., Canada, UK, Germany, China, Japan).. Market for Afib is growing steadily on account of the rising number of Afib cases, which is caused by the lifestyle related diseases, such as hypertension, diabetes, obesity, and is gaining prominence among both adult and aged population. Rising cases of atrial fibrillation (Afib) among the population along with the growing focus on catheter ablation procedures has led to the growth of atrial fibrillation market.. Among the ...
TY - JOUR. T1 - Meta-analysis of randomized controlled trials on atrial fibrillation ablation in patients with heart failure with reduced ejection fraction. AU - Smer, Aiman. AU - Salih, Mohsin. AU - Darrat, Yousef H.. AU - Saadi, Abdulghani. AU - Guddeti, Raviteja. AU - Mahfood Haddad, Toufik. AU - Kabach, Amjad. AU - Ayan, Mohamed. AU - Saurav, Alok. AU - Abuissa, Hussam. AU - Elayi, Claude S.. PY - 2018/11/1. Y1 - 2018/11/1. N2 - Background: The role of catheter ablation (CA) is increasingly recognized as a reasonable therapeutic option in patients with atrial fibrillation (AF) and heart failure (HF). Hypothesis: We aimed to compare CA to medical therapy in AF patients with HF with reduced ejection fraction (HFrEF). Methods: We searched the literature for randomized clinical trials comparing CA to medical therapy in this population. Results: Six trials with a total of 775 patients were included. AF was persistent in 95% of patients with a mean duration of 18.5 ± 23 months prior enrollment. ...
Cardioversion. If a cause cannot be found or easily treated, or if treating the cause does not get rid of the atrial fibrillation, then doctors can use a technique called cardioversion to knock the heart back into a normal rhythm. This involves giving the heart a small electric shock or using medication to force the heart back into normal rhythm.. If this is unsuccessful then the next step particularly in a younger person or someone with simple atrial fibrillation is to do some electrical work, Prof Harbison explained.. Electrical work. Doctors can use what is known as electrophysiology; the study of the electrical function of the heart, to detect the part in the heart that is causing the atrial fibrillation.. Catheter Ablation. They can then use a procedure called catheter ablation which finds and remove the main cause of the atrial fibrillation.. With catheter ablation, narrow, flexible wires, are inserted into a blood vessel, often at the top of your leg or your neck and threaded up to your ...
The CARMA Center at the University of Utah Health Care kicked off a clinical trial aiming to improve the treatment of atrial fibrillation (AF). Under the guidance of lead investigator Nassir Marrouche, M.D., the DECAAF II trial will evaluate the efficacy of targeting atrial fibrotic tissue during catheter ablation of AF in improving procedural outcome.. Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. Each year millions of Americans are diagnosed and treated for this condition, which is an electrical problem in the upper chambers in the heart that causes an irregular heartbeat. Currently one of the most widely used treatments is catheter ablation that involves radiofrequency energy or freezing directed through a catheter to specific heart cells.. In the DECAAF II study two ablation protocols will be compared: the conventional Pulmonary Vein Isolation procedure versus ablation of atrial fibrotic tissue detected using MRI. "This study follows our initial work at ...
Implantable atrial defibrillators are able to deliver shocks immediately after the onset of paroxysmal atrial fibrillation (PAF). It is anticipated that rapid restoration of sinus rhythm may allow electrical remodeling and thus reduce PAF recurrence (sinus rhythm begets sinus rhythm). Methods: 8 patients with atrial defibrillators (Metrix 3020, InControl) were studied for a mean of 11.6+/-3.7 (range 8-18) months. Data were prospectively collected by device telemetry and patient diary. Patient characteristics, PAF episodes and results of device therapy were recorded. Results: All patients had failed | 2 medical therapies. 6/8 patients had structurally normal hearts, 2/8 had dilated left atria and hypertension. Mean number of PAF episodes per month prior to implant was 3.0 (range 0.25-8.0). Post-implant, patients had a mean of 15.4+/-9 (range 0-28) AF episodes during follow-up, with 12.6+/-10.8 attempted therapies with a success rate of 74%. The most common cause of failure of therapy was early
Background: Clinical trials have indicated that an active rhythm control strategy aiming at restoration of sinus rhythm in patients with atrial fibrillation (AF) is no better than a rate-control strategy in terms of mortality and morbidity. To what extent restoration and maintenance of sinus rhythm per se affect long-term prognosis in AF patients is less clear.. Aim: To investigate if there are differences in mortality and morbidity between direct current (DC)-cardioverted AF patients who remain in sinus rhythm after cardioversion and those who relapse early.. Method: 361 cardioverted patients from the Stockholm Cohort Study on Atrial Fibrillation were studied by means of medical records and national registers. Patients were followed for a mean of 4.2 years from DC cardioversion regarding all-cause mortality and for a mean of 3.2 years for a composite endpoint of death, ischaemic stroke, myocardial infarction or hospitalisation for heart failure.. Results: All-cause mortality tended to be lower ...
Atrial Fibrillation: Complications of atrial fibrillation. Atrial fibrillation (also known as AF or AFib) is the most common type of arrhythmia (irregular heartbeat or heart rhythm). The most common symptom of AF is heart palpitations (an irregular and rapid heartbeat, typically experienced as a rapid thumping in the chest). The majority of people with AF live active, healthy lives with treatment.
Shortening of atrial fibrillation cycle length (AFCL) is a marker of atrial electrical remodelling due to atrial fibrillation (AF). To investigate the effect of detomidine administration on AFCL measured invasively from an intra-atrial electrog
Thank you for reading the article Improved Outcomes and Complications of Atrial Fibrillation . And dont forget to share the articles Improved Outcomes and Complications of Atrial Fibrillation If Your articles Improved Outcomes and Complications of Atrial Fibrillation is beneficial for you. Thank You. Thank you for visiting our blog. In the future we continue to seek better in presenting good information. Dont forget to share the article Improved Outcomes and Complications of Atrial Fibrillation this in social media.. Frequently searched keywords:. Nanda Nursing Diagnosis, nanda nursing diagnosis pdf, nanda nursing diagnosis for renal failure, nanda nursing diagnosis for diabetes mellitus, nanda nursing diagnosis for respiratory problems, nanda nursing diagnosis book+free download, nanda nursing diagnosis for respiratory failure, nanda nursing diagnosis list 2015 pdf, nanda nursing diagnosis for atrial septal defect, nanda nursing diagnosis 2015, nanda nursing diagnosis 2015 pdf, nanda nursing ...
BACKGROUND: While tall stature has been related to lower risk of vascular disease, it has been proposed as a risk factor for atrial fibrillation. Little is known about other anthropometric measures and their joint effects on risk for atrial fibrillation. OBJECTIVES: We aim to investigate associations and potential joint effects of height, weight, body surface area (BSA) and body mass index (BMI) with risk of atrial fibrillation. METHODS: In a cohort covering 1,153,151 18-years old men participating in the Swedish military conscription (1972-1995) Cox regression was used to investigate associations of height, weight, BSA and BMI with risk of atrial fibrillation ...
This page includes the following topics and synonyms: Atrial Fibrillation Causes, Atrial Fibrillation Associated Conditions, Atrial Fibrillation Etiology, Atrial Fibrillation Risk Factors.
TY - JOUR. T1 - Female sex as a risk factor for stroke in atrial fibrillation. T2 - a nationwide cohort study. AU - Mikkelsen, Anders. AU - Lindhardsen, J. AU - Lip, G Y H. AU - Gislason, G H. AU - Torp-Pedersen, C. AU - Olesen, J B. N1 - © 2012 International Society on Thrombosis and Haemostasis.. PY - 2012. Y1 - 2012. N2 - Female sex has been suggested as a risk factor for stroke/thromboembolism in patients with non-valvular atrial fibrillation (AF) and has therefore been included within risk scores, e.g., the CHA2 DS2 -VASc score, and guidelines.. AB - Female sex has been suggested as a risk factor for stroke/thromboembolism in patients with non-valvular atrial fibrillation (AF) and has therefore been included within risk scores, e.g., the CHA2 DS2 -VASc score, and guidelines.. U2 - 10.1111/j.1538-7836.2012.04853.x. DO - 10.1111/j.1538-7836.2012.04853.x. M3 - Journal article. VL - 10. SP - 1745. EP - 1751. JO - Journal of Thrombosis and Haemostasis. JF - Journal of Thrombosis and ...
TY - JOUR. T1 - Virtual ablation for atrial fibrillation in personalized in-silico three-dimensional left atrial modeling. T2 - Comparison with clinical catheter ablation. AU - Hwang, Minki. AU - Kwon, Soon Sung. AU - Wi, Jin. AU - Park, Mijin. AU - Lee, Hyun Seung. AU - Park, Jin Seo. AU - Lee, Young Seon. AU - Shim, Eun Bo. AU - Pak, Hui Nam. PY - 2014/9/1. Y1 - 2014/9/1. N2 - Background: Although catheter ablation is an effective rhythm control strategy for atrial fibrillation (AF), empirically-based ablation has a substantial recurrence rate. The purposes of this study were to develop a computational platform for patient-specific virtual AF ablation and to compare the anti-fibrillatory effects of 5 different virtual ablation protocols with empirically chosen clinical ablations. Methods: We included 20 patients with AF (65% male, 60.1±10.5 years old, 80% persistent AF [PeAF]) who had undergone empirically-based catheter ablation: circumferential pulmonary vein isolation (CPVI) for paroxysmal ...
Atrial fibrillation is a heart arrhythmia in which abnormal electrical signals begin in the atria (top chambers) of the heart. Atrial fibrillation may be treated by catheter ablation, if medications alone are not effective. In ablation, areas of tissue in the heart that cause arrhythmias are destroyed.. Before ablation procedure, electrical mapping of the heart is performed. An electrically-sensitive catheter is used to map the heart muscle and the origins of the electrical activity throughout the heart. The map tells the specialist which areas of the heart are creating problematic electric signals that interfere with the proper rhythm.. Catheter ablation is a non-invasive procedure; no major incision is necessary. A surgeon inserts a catheter into the heart via a blood vessel. The surgeon carefully destroys malfunctioning tissue using the catheter to deliver energy (such as radiofrequency, laser or cyrotherapy) to scar the problematic areas. The scarred areas will no longer send abnormal ...
Atrial fibrillation, or Afib, is the most common cardiac arrhythmia, resulting in a fast or irregular heart rhythm among more than 5 million Americans. Afib is traditionally treated with blood-thinners or anticoagulants such as warfarin, but a new device, recently approved by the FDA, is changing the way Afib is treated.. The WATCHMAN™ Left Arial Appendage Closure Device offers patients with non-valvular atrial fibrillation a potentially life-changing stroke risk treatment option that could free them from the challenges of long-term warfarin therapy.. The Frankel Cardiovascular Center is among the first heart centers in the nation to use the WATCHMAN Device. With stroke being one of the most feared consequences of Afib, the WATCHMAN Device has proved to be a viable alternative to blood-thinning medications, which are not well-tolerated by some patients and have a significant risk for bleeding complications. Continue reading →. ...
BACKGROUND AND PURPOSE: Increased visit-to-visit variability in blood pressure (BP) is a powerful risk factor for stroke, but the mechanism is uncertain. We hypothesized that BP variability might affect the risk of new atrial fibrillation (AF). METHODS: We did a systematic review of large randomized controlled trials reporting new-onset AF by treatment allocation, excluding studies in heart failure and acute myocardial infarction. Estimates of the risk of new AF by treatment allocation were related to effects of treatment on group variability in BP. RESULTS: Of 94 eligible randomized controlled trials, 14 reported rates of new AF. Although there was considerable heterogeneity between trials in effects of treatment on variance ratio (P|0.0001), lower variance ratio was unrelated to new-onset AF either on meta-analysis (OR=1.02; 95% CI 0.90 to 1.15; 125 878 patients; 13 comparisons) or on metaregression (log OR versus log variance ratio of systolic blood pressure r(2)=0.109, P=0.270). Angiotensin receptor
In this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium.
OBJECTIVES: The aim of this study was to evaluate dabigatran dual therapy versus warfarin triple therapy in patients with or without diabetes mellitus in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.. BACKGROUND: It is unclear whether dual therapy is as safe and efficacious as triple therapy in patients with atrial fibrillation with diabetes following percutaneous coronary intervention.. METHODS: In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor). Median follow-up was 13 months. The primary outcome was the composite of major bleeding or clinically relevant nonmajor bleeding, and the ...
The afibbers.org database. Useful, authoritative information about atrial fibrillation, lone atrial fibrillation, paroxysmal atrial fibrillation and their prevention and treatment
Find and save ideas about Atrial fibrillation on Pinterest. | See more ideas about Cardiac nursing, Beta blockers and Paramedic student.
The global atrial fibrillation market is expected to reach USD 16.17 billion by 2020. Rising occurrence of strokes, brain damage and atrial fibrillation owing to blood clots along with an increasing geriatric population is expected to drive industry growth. Technological advancements in the field of microwave catheter ablation and radiofrequency along with rising occurrence of diseases caused by lifestyle habits such as drinking and smoking are further expected to fuel growth. Moreover, increasing demand for smaller cardiac incisions, minimally invasive procedures and small recovery time post-surgery are projected to bolster growth. Also, global aging population combined with the changes in lifestyle increasing the risks of obesity and high blood pressure is likely to drive demand.. Full research report on atrial fibrillation market Analysis: http://www.grandviewresearch.com/industry-analysis/atrial-fibrillation-treatment-industry. Pharmacological products accounted for over 50% market share in ...
AIMS: To assess clinical outcomes, efficacy, and safety according to sex during anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation.. METHODS AND RESULTS: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) was a randomized, double-blind, placebo-controlled, multicentre trial that included 11 785 (64.7%) men and 6416 (35.3%) women with atrial fibrillation or flutter randomized to receive either warfarin or apixaban. The primary efficacy endpoint was stroke or systemic embolism; secondary efficacy endpoints were death from any cause and cardiovascular death. The primary safety endpoint was major bleeding; secondary safety endpoints were a composite of major bleeding and non-major clinically relevant bleeding. The risk of stroke or systemic embolism was similar in women vs. men [adjusted hazard ratio (adjHR): 0.91; 95% confidence interval (CI): 0.74-1.12; P = 0.38]. However, among patients with history of stroke ...
Acute atrial fibrillation (AF) is the most common cardiac rhythm encountered in clinical practice and is commonly seen in acutely ill patients in critical care. In the latter setting, AF may have two main clinical sequelae: (1) haemodynamic instability and (2) thromboembolism. The approach to the management of AF can broadly be divided into a rate control strategy or a rhythm control strategy, and is largely driven by symptom assessment and functional status. A crucial part of AF management requires the appropriate use of thromboprophylaxis. In patients who are haemodynamically unstable with AF, urgent direct current cardioversion should be considered. Apart from electrical cardioversion, drugs are commonly used, and Class I (flecainide, propafenone) and Class III (amiodarone) antiarrhythmic drugs are more likely to revert AF to sinus rhythm. Beta blockers and rate limiting calcium blockers, as well as digoxin, are often used in controlling heart rate in patients with acute onset AF. The aim of this
Isabelle C. Van Gelder, M.D., Vincent E. Hagens, M.D., Hans A. Bosker, M.D., J. Herre Kingma, M.D., Otto Kamp, M.D., Tsjerk Kingma, M.Sc., Salah A. Said, M.D., Julius I. Darmanata, M.D., Alphons J.M. Timmermans, M.D., Jan G.P. Tijssen, Ph.D., Harry J.G.M. Crijns, M.D., for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group ABSTRACT Background Maintenance of sinus rhythm is the main therapeutic goal in patients with atrial fibrillation. However, recurrences of atrial fibrillation and side effects of antiarrhythmic drugs offset the benefits of sinus rhythm. We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation.. Methods We randomly assigned 522 patients who had persistent atrial fibrillation after a previous electrical cardioversion to receive treatment aimed at rate control or rhythm control. Patients in the rate-control group received oral anticoagulant drugs and ...
Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation (AF) has today reaffirmed its commitment to tackling this new millennium epidemic by launching two major initiatives to coincide with Global AF Aware Week, 18-24 November 2019. Get Smart About AFIB (GSAAF) is a campaign where Arrhythmia Alliance and Biosense Webster have partnered to improve knowledge of AF across the healthcare community and the general public. Alongside this campaign, the Atrial Fibrillation Management Report examines the available treatment options for AF across Europe and their long-term impact on clinical, patient and economic outcomes, aiming to support healthcare professionals (HCPs) when making treatment decisions. The Atrial Fibrillation Management Report reviewed independent studies to explore current treatment options for AF patients, which include antiarrhythmic drugs (AADs) and catheter ablation. Key findings highlighted that just half of
Q: Our facility is developing clinical definitions regarding types of atrial fibrillation (afib) given the specificity changes in ICD-10. Could you provide suggestions for these definitions? Do you think is it appropriate to query for persistent atrial fibrillation for the period of more than seven days and chronic afib sustained more than 12 months duration? Are you aware of any strategies other institutions are using when querying regarding atrial fibrillation?
A cardiac implant device is provided in which the ventricular rate is monitored to differentiate between atrial fibrillation and ventricular tachycardia or other cardiac conditions. For this purpose, the ventricular rate stability is monitored by, for example, measuring the R-R intervals of successive ventricular beats. If the ventricular rate is found to be unstable, the ventricle is paced at a test rate to try to stabilize the ventricle. If the attempt is unsuccessful, atrial fibrillation is assumed and, if necessary, corresponding therapy is applied. If the attempt is unsuccessful, atrial fibrillation is eliminated as a cause of the ventricular rate instability and other types of classifying and treating the cardiac condition may be used.
Atrial fibrillation is the most common heart rhythm disturbance.1 It is a serious, but very treatable heart condition. Many people have Atrial Fibrillation (called AFib or AF) but dont even realize it. If left untreated, the effects of AFib can be life threatening. To help improve public education and awareness, Congress passed two resolutions beginning in 2009, designating September as Atrial Fibrillation Awareness Month. The purpose is to educate more people about this condition and to help prevent the potentially devastating consequences if left unrecognized and untreated.. In AFib, there is a problem with the electrical system in the atria causing the heart to pump irregularly. This problem can cause the top chambers to quiver or jiggle, which is described as an irregular heartbeat or arrhythmia. When the heart doesnt pump normally, it causes blood to sit in the top chambers of the heart longer than it should. Blood sitting can lead to blood clots, stroke, heart failure and other ...
Surprisingly little information on symptoms of paroxysmal atrial fibrillation is available in scientific literature. Using questionnaires, we have analyzed the symptoms associated with arrhythmia attacks. One hundred randomly-selected patients with idiopathic paroxysmal atrial fibrillation filled in a structured questionnaire. Psychic stress was the most common factor triggering arrhythmia (54%), followed by physical exertion (42%), tiredness (41%) coffee (25%) and infections (22%). Thirty-four patients cited alcohol, 26 in the form of red wine, 16 as white wine and 26 as spirits. Among these 34, red wine and spirits produced significantly more episodes of arrhythmia than white wine (p = 0.01 and 0.005 respectively). Symptoms during arrhythmia were palpitations while exerting (88%), reduced physical ability (87%), palpitations at rest (86%), shortage of breath during exertion (70%) and anxiety (59%). Significant differences between sexes were noted regarding swollen legs (women 21%, men 6%, p = 0.027),
In the current study, Dr. Kamel et al evaluate the relationship between left atrial disease, as measured by P-wave terminal force in lead V1, and the risk of stroke while adjusting for atrial fibrillation and other stroke risk factors. P-wave terminal force is an established electrocardiographic marker of left atrial cardiomyopathy without necessarily having atrial fibrillation and can be easily calculated on a standard EKG. In order to test the hypothesis that atrial disease may lead to thromboemoblism without atrial fibrillation, atrial disease should be specifically associated with cardioembolic or cryptogenic stroke subtypes as opposed to non-cardioembolic stroke subtypes. The authors measured the P-wave terminal force in 241 patients with ischemic stroke and a randomly selected cohort of 798 patients without ischemic stroke. P-wave terminal force in lead V1was indeed associated with the composite of cryptogenic and cardioemoblic stroke, but not non-cardioembolic stroke subtypes. In ...
Atrial fibrillation slow ventricular response - Does atrial fibrillation with rapid ventricular response cause ventricular fibrillation? Only in a Very Few. Generally, the answer to this is a very solid "no." this is a rare complication of people with another condition (on top of their afib) called wolff-parkinson-white syndrome (or wpw). In certain patients having both conditions, the top chamber is too-well connected to the bottom and can trigger ventricular fibrillation.
FDA has approved the anticlotting drug edoxaban to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem.. Edoxaban also has been approved to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have already been treated with an anticlotting drug administered by injection or infusion for 5 to 10 days.. Safety and efficacy of edoxaban in treating patients with atrial fibrillation not caused by cardiac valve disease was studied in a clinical trial of 21,105 participants.The trial compared two dose levels of edoxaban with the anticlotting drug warfarin for their effects on rates of stroke and dangerous blood clots.. Trial results showed the higher dose of edoxaban to be similar to warfarin for the reduction in the risk of stroke. While warfarin is highly effective in reducing the risk of stroke in patients with atrial fibrillation, it increases the risk of bleeding. Edoxaban demonstrated ...
Recent years have seen an enormous amount of experimental and clinical research into role of the pulmonary veins (PVs) in atrial fibrillation (AF). The PVs contain cardiomyocytes with easily inducible arrhythmogenic activity due to the enhanced autom
Atrial Fibrillation: Preventing blood clots. Most people with atrial fibrillation (also known as AF or AFib) need to take anticoagulants or antiplatelets. The main goal of these medications, known as blood thinners, is to reduce your risk of stroke. In addition to atrial fibrillation, other risk factors for stroke include high blood pressure, diabetes, heart failure, age (over 75 years), and prior stroke or transient ischemic attack (TIA, or mini-stroke).
Press Release issued Sep 10, 2013: Atrial fibrillation (AF) is characterized by irregular and often rapid heart rate responsible for poor blood flow to the body and is one of the most common types of arrhythmia. It occurs in cases where the -hearts electrical signals cause the atria to fibrillate, i.e. contract irregularly and very fast. The risk of developing atrial fibrillation usually occurs in the geriatric population and its risk is high in patients with mitral valve diseases, coronary heart disorder, congenital heart disease, cardiomyopathy, etc. Atrial fibrillation is also characterized by collection of blood in the atria and as a result there is absence of synchronization between the upper and lower chambers of the heart thereby increasing the risk of stroke.
The Global Atrial Fibrillation Market is expected to reach USD 16.17 billion by 2020 growing at a CAGR of 13.2%, according to a new study by Grand View Research, Inc. Growing incidences of atrial fibrillation, strokes and brain damage due to blood clots coupled with a growing global base of geriatric population is expected to be a key driver for this market. Some of the other drivers of this market include the introduction of technological advancements in the fields of radiofrequency and microwave catheter ablation, growing demand for minimally invasive procedures and increasing prevalence of disease causing lifestyle habits such as smoking and excessive alcohol consumption. Pharmacological products for Atrial Fibrillation dominated the overall market in terms of revenue in 2013 at over 55.0%. Relatively low prices associated with these products and the use of anti-coagulants as an add-on therapy to non-pharmacological procedures, are some of the drivers of this segment.. Full research report on ...
The Global Atrial Fibrillation Market is expected to reach USD 16.17 billion by 2020 growing at a CAGR of 13.2%, according to a new study by Grand View Research, Inc. Growing incidences of atrial fibrillation, strokes and brain damage due to blood clots coupled with a growing global base of geriatric population is expected to be a key driver for this market. Some of the other drivers of this market include the introduction of technological advancements in the fields of radiofrequency and microwave catheter ablation, growing demand for minimally invasive procedures and increasing prevalence of disease causing lifestyle habits such as smoking and excessive alcohol consumption. Pharmacological products for Atrial Fibrillation dominated the overall market in terms of revenue in 2013 at over 55.0%. Relatively low prices associated with these products and the use of anti-coagulants as an add-on therapy to non-pharmacological procedures, are some of the drivers of this segment.. ...
New-onset AF occurred in 5.9% of patients with severe sepsis. The in-hospital stroke rate was 2.6% in patients with new-onset AF, 0.6% in patients with pre-existing AF, and 0.7% in patients with no AF. After adjusting for multiple confounding variables, new-onset AF was independently and significantly associated with a 2.7-fold increase in the risk of stroke and a 7% increase in the risk of in-hospital mortality.. ...
Atrial fibrillation (AF), a common type of heart arrhythmia, is a major risk factor for stroke. About 15 percent of all strokes are attributable to atrial fibrillation. Anticoagulants such as Warfarin, as well as beta blockers and calcium channel blockers, may be prescribed to reduce the risk of stroke. How common is atrial fibrillation? Data from the Framingham Heart Study, which followed over 8,000 Massachusetts residents from 1966-1999, indicate that the average lifetime risk after age 40 was 26% for men and 23% for women, and that the risk remained relatively constant as individuals grew older. [PMID 15313941] ...
What is atrial fibrillation (AF)? Learn more about these heart flutters and palpitations, the causes of atrial fibrillation, and more.
Atrial fibrillation patient videos - How StopAfib.org Can Help You, Atrial Fibrillation Patient Perspective, What You Dont Know About Atrial Fibrillation Could Kill You, Take a Stand Against Afib Strokes
Hello, are you looking for article Improved Outcomes and Complications of Atrial Fibrillation ? If it is true we are very fortunate in being able to provide information Improved Outcomes and Complications of Atrial Fibrillation And good article Improved Outcomes and Complications of Atrial Fibrillation This could benefit/solution for you. ...
What is atrial fibrillation? Learn atrial fibrillation (A-fib) treatment, symptoms, guidelines, and ablation. What causes atrial fibrillation?
Hello, are you looking for article EKG showing Atrial Fibrillation, HR irregular 130160s, and clinic? If it is true we are very fortunate in being able to provide information EKG showing Atrial Fibrillation, HR irregular 130160s, and clinic And good article EKG showing Atrial Fibrillation, HR irregular 130160s, and clinic This could benefit/solution for you. ...
Hello, are you looking for article EKG showing Atrial Fibrillation, HR irregular 130160s, and clinic? If it is true we are very fortunate in being able to provide information EKG showing Atrial Fibrillation, HR irregular 130160s, and clinic And good article EKG showing Atrial Fibrillation, HR irregular 130160s, and clinic This could benefit/solution for you. ...
Treatment of atrial fibrillation is complex and depends on factors such as whether the patient is currently experiencing symptoms, how long the patient has been in atrial fibrillation, the overall health of the patient, and the size and function of the hearts chambers.
Hello, are you looking for article ATRIAL FIBRILLATION NURSING image galleries imageKB.com? If it is true we are very fortunate in being able to provide information ATRIAL FIBRILLATION NURSING image galleries imageKB.com And good article ATRIAL FIBRILLATION NURSING image galleries imageKB.com This could benefit/solution for you. ...
Hello, are you looking for article atrial fibrillation? If it is true we are very fortunate in being able to provide information atrial fibrillation And good article atrial fibrillation This could benefit/solution for you. ...
MUNICH, January 16, 2012 /PRNewswire/ --. - For European Media Only -- Collection of real life data from 5,000 atrial fibrillation patients (AF) across seven countries will generate invaluable insights into one of Europes leading causes of stroke(1,2) -- Daiichi Sankyo Europe GmbH today announced the enrolment of the first patient into the PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).(1) Taking a comprehensive approach to the patient registry, PREFER in AF will gather data on the full spectrum of AF patients including those with valvular and non valvular forms of the condition.(1) The registry will also track the impact of new anticoagulant therapies on stroke prevention, (1) in addition to collating insights into patients satisfaction with their entire AF management, the impact of AF and its management on patient quality of life, (1) and the overall health economic burden of AF across Europe.(1) In 2010, the World Heart Federation highlighted ...
Medline: [exp Atrial fibrillation OR AF.mp OR atrial fibrillation.mp] AND [exp electric countershock OR cardioversion.mp OR exp anti arrhythmia agents OR chemical cardioversion.mp] AND [exp heparin OR heparin.mp OR exp heparin, low molecular weight OR low molecular weight heparin.mp OR fractionated heparin.mp OR bemiparin.mp OR certoparin.mp OR dalteparin.mp OR oxaparin.mp OR reviparin.mp OR tinzaparin.mp OR fragmin.mp OR clexane.mp OR exp warfarin or warfarin.mp OR exp coumarins OR coumarins.mp OR exp aspirin OR aspirin.mp] LIMIT to human AND English language ...
Current guidlines recommend a patient-specific approach to treating atrial fibrillation. A rate control (allowing the patient to remain in atrial fibrillation, ensuring the heart rate is controlled) or rhythm control (using specfic medications or procedures to restore normal rhythm) strategy may be adopted. Your doctor will decide which treatment approach is most appropriate for you. Medications are usually used with the rate control strategy, commonly including beta-blocker medication, such as atenolol or metoprolol, or calcium-channel blockers, such as diltiazem or verapamil, to slow down the heart rate.. The rhythm control strategy may include the use of medications (anti-arrhythmics) or electrical cardioversion to restore normal rhythm. Catheter ablation (a catheter is guided through a blood vessel to the heart and energy is sent through the catheter to destroy small areas of heart tissue that may cause the arrhythmia) is a nonsurgical procedure that is commonly used when medications are not ...
Atrial fibrillation can be caused by sleep apnea therefore 100% of patients with SAtrial Fibrillation should be evaluated for sleep apnea. Patients with Atrial Fibrillation should be tested even if they have none of the commonly seen symptoms of apnea such as snoring, excessive tirednedd, weight gain or hypertension. Many patients have sleep apnea but do not fit picture often associated with apnea. Unfortunately while the percentage of patients with sleep apnea in cardiology offices may be as high as 70% it is estimated only 10-20% are ever diagnosed. I have recently created a new company Sleep Well Illinois to set up UNIVERSAL SLEEP APNEA SCREENING IN CARDIOLOGY PRACTICES AND INTERNAL MEDICINE OFFICES. https://www.sleepandhealth.com/node/653. Universal screening for sleep apnea can be done with a simple questionnaire and at risk patients can have a portable sleep test in the comfort of their own home in their own bed. Most patients have mild to moderate sleep apnea and do not require CPAP. ...
The FDA has approved Bristol-Myers Squibb and Pfizers anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem.. "Blood clots in the heart can cause a disabling stroke if the clots travel to the brain," said Norman Stockbridge, M.D., Ph.D., director of the division of cardiovascular and renal products in the FDAs Center for Drug Evaluation and Research. "Anti-clotting drugs lower the risk of having a stroke by helping to prevent blood clots from forming.". The safety and efficacy of Eliquis in treating patients with atrial fibrillation not caused by cardiac valve disease were studied in a clinical trial of more than 18,000 patients that compared Eliquis with the anti-clotting drug warfarin. In the trial, patients taking Eliquis had fewer strokes than those who took warfarin.. Patients with prosthetic heart valves should not take Eliquis nor should patients ...
The management of atrial fibrillation (AF) is focused on preventing temporary circulatory instability and to prevent stroke and other ischemic events. Control of heart rate and rhythm are principally used to achieve the former, while anticoagulation may be employed to decrease the risk of stroke. Within the context of stroke, the discipline may be referred to as stroke prevention in atrial fibrillation (SPAF). In emergencies, when circulatory collapse is imminent due to uncontrolled rapid heart rate, immediate cardioversion may be indicated. The primary factors determining AF treatment are duration and evidence of circulatory instability. Cardioversion is indicated with new onset AF (for less than 48 hours) and with circulatory instability. If rate and rhythm control cannot be maintained by medication or cardioversion, it may be necessary to perform electrophysiological studies with ablation of abnormal electrical pathways. Most patients with AF are at increased risk of stroke. The possible ...
Until recently, vitamin K antagonists were the only available oral anticoagulants, but with numerous limitations that prompted the introduction of new oral anticoagulants targeting the single coagulation enzymes thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban, and edoxaban) and given in fixed doses without coagulation monitoring. Here we review the pharmacology and the results of clinical trials with these new agents in stroke prevention in atrial fibrillation and secondary prevention after acute coronary syndromes, providing perspectives on their future incorporation into clinical practice. In phase III trials in atrial fibrillation, compared with warfarin, dabigatran etexilate 150 mg B.I.D. reduced the rates of stroke/systemic embolism without any difference in major bleeding; dabigatran etexilate 110 mg B.I.D. had similar efficacy with decreased bleeding; apixaban 5 mg B.I.D. reduced stroke, systemic embolism, and mortality as well as major bleeding; and rivaroxaban 20 mg Q.D. was
BACKGROUND: Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes. METHODS: We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71 683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative
Im 64 and have had lone atrial fibrillation for about a decade. My doctor wants me to take a blood thinner, but Id rather not do this. Should I follow…
Im 64 and have had lone atrial fibrillation for about a decade. My doctor wants me to take a blood thinner, but Id rather not do this. Should I follow…
Novel smartphone and tablet applications (apps) for atrial fibrillation patients and healthcare professionals have been launched by heart experts. The objectives and design of the apps are outlined in a paper published online today in EP Europace,1 with a summary published in the European Heart Journal.2
Nearly 40 percent of patients treated with aspirin alone despite previous data showing blood thinners more beneficial. Patients who have been diagnosed with atrial fibrillation (AF) are seven times more likely to have a stroke based on the chaotic electrical impulses that occur in the upper chambers of the heart. Because of these impulses, the heart cannot pump blood as efficiently to the lower chambers causing an increased chance that blood clots could form. In order to prevent that, patient with AF are treated with blood thinners. However, this study showed that one in three patients were actually being treated with just aspirin alone. "Stroke prevention is critical to the management of AF patients. However, giving aspirin alone to this population may not be the best treatment therapy because it is either minimally effective or not effective at all and still comes with risks, such as intracranial hemorrhage," said lead author Jonathan C. Hsu, MD, cardiologist at UC San Diego Health and ...
An abnormally rapid ventricular cardiac rate that results from atrial fibrillation can be reduced by stimulating a vagal nerve of the heart. An apparatus for such stimulation includes a power transmitter that emits a radio frequency signal. A stimulator, implanted in a blood vessel adjacent the vagal nerve, has a pair of electrodes and an electrical circuit thereon. The electrical circuit receives the radio frequency signal and derives an electrical voltage from the energy of that signal. The electrical voltage is applied in the form of pulses to the pair of electrodes, thereby stimulating the vagal nerve. The pattern of that stimulating pulses can be varied in response to characteristics of the atrial fibrillation or the ventricular contractions.
One-third of patients dont know the stroke symptoms to look for, and surveyed doctors say their atrial fibrillation patients dont understand stroke risk.
Atrial fibrillation can lead to stroke, so you dont want to ignore the signs. Learn when to call your doctor with atrial fibrillation symptoms.
Researchers believe cardiology specialists may be unaware of risk -- About one quarter of all atrial fibrillation patients at the lowest risk for stroke receive unnecessary blood thinners from cardiology specialists, according to a new study by researchers at University of California, San Diego School of Medicine and University of California, San Francisco, and these…
BACKGROUND: Evidence is conflicting as to the efficacy of direct oral anticoagulation (DOAC) and vitamin K antagonist (VKA) for prevention of myocardial infarction (MI).. OBJECTIVES: This study aimed to investigate the risk of MI associated with the use of apixaban, dabigatran, rivaroxaban, and VKA in patients with atrial fibrillation.. METHODS: Patients with atrial fibrillation were identified using Danish health care registers and stratified by initial oral anticoagulant treatment. Standardized absolute 1-year risks were estimated based on Cox regression for hazard rates of MI hospitalizations and mortality. Reported were absolute risks separately for the oral anticoagulation treatments and standardized to the characteristics of the study population.. RESULTS: Of the 31,739 patients included (median age, 74 years; 47% females), the standardized 1-year risk of MI for VKA was 1.6% (95% confidence interval [CI]: 1.3 to 1.8), apixaban was 1.2% (95% CI: 0.9 to 1.4), dabigatran was 1.2% (95% CI: 1.0 ...
1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-76 2. Benjamin EJ, Wolf PA, DAgostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-52 3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8 4. Alegret JM, Viñolas X, Arias MA, Martínez-Rubio A, Rebollo P, Ràfols C, Martínez-Sande JL. New oral anticoagulants vs vitamin K antagonists: ...
TY - JOUR. T1 - Clinical significance of additional ablation of atrial premature beats after catheter ablation for atrial fibrillation. AU - Kim, In Soo. AU - Yang, Pil Sung. AU - Kim, Tae Hoon. AU - Park, Junbeum. AU - Park, Jin Kyu. AU - Uhm, Jae Sun. AU - Joung, Boyoung. AU - Lee, Moon Hyoung. AU - Pak, Hui Nam. PY - 2016/1. Y1 - 2016/1. N2 - Purpose: The clinical significance of post-procedural atrial premature beats immediately after catheter ablation for atrial fibrillation (AF) has not been clearly determined. We hypothesized that the provocation of immediate recurrence of atrial premature beats (IRAPB) and additional ablation improves the clinical outcome of AF ablation. Materials and Methods: We enrolled 200 patients with AF (76.5% males; 57.4±11.1 years old; 64.3% paroxysmal AF) who underwent catheter ablation. Post-procedure IRAPB was defined as frequent atrial premature beats (≥6/min) under isoproterenol infusion (5 μg/min), monitored for 10 min after internal cardioversion, and ...
1. Study name: Intensive management of blood pressure and cholesterol in elderly Chinese with hypertension and atrial fibrillation (IMPRESSION) 2. Medicine: amlodipine/atorvastatin (5/10mg tablet); amlodipine/atorvastatin (5/20mg tablet); allisartan (240mg/tablet). 3. Rationale: controlling blood pressure and cholesterol are both effective means to reduce cardiovascular risks, however, it is still unknown whether high cardiovascular risk patients with atrial fibrillation would benefit from intensive management of blood pressure and cholesterol. 4. Objective: To evaluate the efficacy and safety of intensive management of blood pressure and cholesterol. 5. Study design: This study is a multi-center, randomized and controlled clinical trial with four equally sized treatment groups: amlodipine/atorvastatin (5/10mg tablet); amlodipine/atorvastatin (5/20mg tablet); amlodipine
Objective: To compare the value of current harmonic transthoracic and transesophageal echocardiography for assessing echocardiographic markers of thromboembolic risk and identify left atrial thrombi in patients with atrial fibrillation and atrial flutter prior to cardioversion and/or overdrive stimulation. Transesophageal echocardiography has been suggested for guiding cardioversion in patients with atrial fibrillation and atrial flutter, because of its high accuracy for identifying left atrial thrombi. More recent studies have demonstrated that harmonic echocardiography may allow transthoracic detection of left atrial thrombi and assessment of left atrial appendage function. Setting: Tertiary cardiac referral centre. 172 Patients with atrial fibrillation and/or atrial flutter who were scheduled for cardioversion and/or overdrive stimulation were examined both by harmonic transthoracic and multiplane transesophageal echocardiography by independent observers to assess left atrial chamber and ...
The final diagnosis was AL (primary) amyloidosis and smoldering multiple myeloma with cardiac involvement. Treatment was started with CYBord (velcade, cytoxan, dexamethasone). Enoxaparin therapy was started for the left atrial appendage thrombus. Given major cardiac involvement, and a clinically estimated 5 yr overall survival of 40%, ICD implantation for primary prevention was not recommended. Perspective: Several key findings of cardiac amyloidosis were identified in this study. Atrial fibrillation is common in this population, for which real-time cine imaging was helpful. CMR has not gained widespread use for LAA thrombus detection, despite prior reports suggesting high sensitivity and specificity. This may be attributable to the overall low incidence of thrombus in study populations comparing CMR to transesopohageal echocardiography2. With the addition of three dimensional contrast MRA, which was not performed in this study, detection may approach that of transesophageal echocardiography. ...
Find the best radiofrequency catheter ablation doctors in Thane. Get guidance from medical experts to select radiofrequency catheter ablation specialist in Thane from trusted hospitals - credihealth.com
Below you find the De Voogt ECG Archive which contains more than 2000 ECGs. This archive was collected by W.G. de Voogt, MD, PhD and is available under a creative commons license. This archive is a work in progress. ECGs may have ended up in the wrong category and descriptions are often missing. * Arrhythmias ** Supraventricular *** [[De Voogt ECG Archive - Supraventricular Rhythms - AF,atrial fibrillation]] *** [[De Voogt ECG Archive - Supraventricular Rhythms - Atrial flutter,atrial flutter]] *** [[De Voogt ECG Archive - Supraventricular Rhythms - Atrial rhythm,atrial rhythm]] *** [[De Voogt ECG Archive - Supraventricular Rhythms - Atrial tachycardia,atrial tachycardia]] *** [[De Voogt ECG Archive - Supraventricular Rhythms - AVNRT,AVNRT]] *** [[De Voogt ECG Archive - Supraventricular Rhythms - AVRT,AVRT]] *** [[De Voogt ECG Archive - Supraventricular Rhythms - Holter,Holter]] *** [[De Voogt ECG Archive - Supraventricular Rhythms - Parasystole,parasystole]] *** [[De Voogt ECG Archive - ...
Relative contributions of the atria and the atrioventricular (AV) node to AV conduction were studied in isolated, blood-perfused dog hearts. The functional refractory period of the atria, although shorter than that of the AV node, determined the functional refractory period of the entire transmission system in 50% of the hearts. Slow atrial conduction of early beats greatly influenced the shape of the curve used to determine the functional refractory period of the transmission system. The atrial effective refractory period was also shorter than the effective refractory period of the AV node. However, the effective refractory period of the entire transmission system was equal to that of the atrium when the driving interval was longer than 320 msec, and it decreased as the driving interval was shortened. At driving intervals of 320 msec or less, the effective refractory period of the AV transmission system abruptly increased and became equal to the effective refractory period of the node. ...
TY - JOUR. T1 - Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. AU - Avecilla, Scott T.. AU - Ferrell, Chris. AU - Chandler, Wayne L.. AU - Reyes Gil, Morayma. PY - 2012/4. Y1 - 2012/4. N2 - New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs. Copyright. AB - New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the ...

Clinical significance of additional ablation of atrial premature beats after catheter ablation for atrial fibrillation<...Clinical significance of additional ablation of atrial premature beats after catheter ablation for atrial fibrillation<...

Clinical significance of additional ablation of atrial premature beats after catheter ablation for atrial fibrillation. In: ... Clinical significance of additional ablation of atrial premature beats after catheter ablation for atrial fibrillation. Yonsei ... Clinical significance of additional ablation of atrial premature beats after catheter ablation for atrial fibrillation. / Kim, ... title = "Clinical significance of additional ablation of atrial premature beats after catheter ablation for atrial fibrillation ...
more infohttps://yonsei.pure.elsevier.com/en/publications/clinical-significance-of-additional-ablation-of-atrial-premature-

Atrial Fibrillation | Risk | Framingham Heart StudyAtrial Fibrillation | Risk | Framingham Heart Study

Heart Failure in Atrial Fibrillation. (10-year risk). (based on Schnabel RB, Rienstra M, Sullivan LM, Sun JX, Moser CB, Levy D ... Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail. 2013;15:843-849. PMID ... Participants with manifest atrial fibrillation free of heart failure at baseline, aged 39 to 96 years ... Atrial Fibrillation *Framingham Heart Study AF score. (10-year risk). *Heart Failure in Atrial Fibrillation (10-year risk) ...
more infohttps://www.framinghamheartstudy.org/risk-functions/atrial-fibrillation/heart-failure-afib.php

Atrial Fibrillation | cdc.govAtrial Fibrillation | cdc.gov

Learn about atrial fibrillation, often called AFib or AF, the most common type of treated heart arrhythmia. ... What is atrial fibrillation?. Atrial fibrillation, often called AFib or AF, is the most common type of treated heart arrhythmia ... Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8. ... Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the ...
more infohttps://www.cdc.gov/heartdisease/atrial_fibrillation.htm

Atrial FibrillationAtrial Fibrillation

In atrial fibrillation, your pulse often doesnt match your heart sounds. The diagnosis of atrial fibrillation is usually ... Some people with atrial fibrillation have periods of normal heartbeats: the atrial fibrillation comes and goes. In many others ... For anyone who has chronic atrial fibrillation, or who may be going in and out of atrial fibrillation without knowing it ( ... However, atrial fibrillation is often a lifelong condition. This is more likely when it has no known cause or results from a ...
more infohttps://www.womenshealthmag.com/health/a19949249/atrial-fibrillation/

Managing Atrial FibrillationManaging Atrial Fibrillation

Learn about the role of inflammation in atrial fibrillation, AF in athletes, nuances of rate control, progress in ablation, and ... atrial fibrillation in patients with type 2 diabetes mellitus. The combination of atrial fibrillation and diabetes confers an ... A patient with atrial fibrillation with a CHADS2 score of 3 is taking warfarin. She hasnt had a prior episode of ... Atrial fibrillation (AF) has been linked with an increased risk for cognitive impairment and dementia in numerous studies over ...
more infohttps://www.medpagetoday.com/resource-center/afib

Managing Atrial FibrillationManaging Atrial Fibrillation

Learn about the role of inflammation in atrial fibrillation, AF in athletes, nuances of rate control, progress in ablation, and ... atrial fibrillation in patients with type 2 diabetes mellitus. The combination of atrial fibrillation and diabetes confers an ... A patient with atrial fibrillation with a CHADS2 score of 3 is taking warfarin. She hasnt had a prior episode of ... Atrial fibrillation (AF) has been linked with an increased risk for cognitive impairment and dementia in numerous studies over ...
more infohttps://www.medpagetoday.com/resource-center/managing-afib?eun=g371412d0reun=g371412d0r&xid=NL_MPT_IH_2014-08-07

Common Atrial Fibrillation MedicationsCommon Atrial Fibrillation Medications

Medications for atrial fibrillation can help control your heart rate, and also help prevent blood clots. Well detail the most ... Atrial fibrillation (or AFib) is a condition that causes an irregular, fast heart rate and rhythm. It also causes issues with ... In AFib, the chaotic atrial electrical activity in your heart stops the atria from contracting well. This causes blood to move ...
more infohttps://www.healthline.com/health/living-with-atrial-fibrillation/medication-guide

Asthma, Atrial Fibrillation ConnectionAsthma, Atrial Fibrillation Connection

Millard concludes "Atrial fibrillation occurred in less than five percent of the entire study population, which is pretty low." ... There May Be No Permanent Cure for Atrial Fibrillation. Researchers say even after irregular heartbeats are treated, they can ... The Link Between Asthma and Atrial Fibrillation. Written by George Citroner. on July 16, 2018 ... states that poorly controlled asthma also brings a significantly increased risk of atrial fibrillation (AFib). ...
more infohttps://www.healthline.com/health-news/link-between-asthma-and-atrial-fibrillation

Atrial Fibrillation - Multiple Languages: MedlinePlusAtrial Fibrillation - Multiple Languages: MedlinePlus

Health Information on Atrial Fibrillation: MedlinePlus Multiple Languages Collection ... Atrial Fibrillation: MedlinePlus Health Topic - English Fibrilación auricular: Tema de salud de MedlinePlus - español (Spanish) ... Atrial Fibrillation - 简体中文 (Chinese, Simplified (Mandarin dialect)) Bilingual PDF ... Atrial Fibrillation - 繁體中文 (Chinese, Traditional (Cantonese dialect)) Bilingual PDF ...
more infohttps://medlineplus.gov/languages/atrialfibrillation.html

Atrial Fibrillation | CirculationAtrial Fibrillation | Circulation

Atrial fibrillation begets atrial fibrillation: a study in awake, chronically instrumented goats. Circulation. 1995;92:1954- ... Recently, Wijffels et al8 showed that induction of atrial fibrillation by intermittent rapid atrial pacing in goats led to a ... Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc ... Nevertheless, it offers the possibility of eradicating atrial fibrillation without surgery.. Atrial RFCA also vagally ...
more infohttp://circ.ahajournals.org/content/95/3/562

Atrial FibrillationAtrial Fibrillation

... (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can ... Even though untreated atrial fibrillation doubles the risk of heart-related deaths and is associated with a 5-fold increased ... In atrial fibrillation, the upper chambers of the heart (the atria) beat irregularly (quiver) instead of beating effectively to ... Atrial fibrillation (AFib) is the most common type of irregular heartbeat. The abnormal firing of electrical impulses causes ...
more infohttps://www.stvincent.org/Services/Cardiovascular-Services/Atrial-Fibrillation

Atrial Fibrillation (AFib)Atrial Fibrillation (AFib)

... is an abnormal heart rhythm. The four chambers of the heart usually beat in a steady, rhythmic ... Stroke is the greatest risk for the patient with atrial fibrillation. Some patients are not aware of atrial fibrillation and in ... Atrial Fibrillation (A Fib) is one of the most common abnormal heart rhythms, particularly once a person reaches the age of 65 ... Click the image to view an animation on Atrial Fibrillation The heart is a pump, and in order to function efficiently, it is ...
more infohttps://www.hrsonline.org/Patient-Resources/Heart-Diseases-Disorders/Atrial-Fibrillation-AFib

Atrial FibrillationAtrial Fibrillation

Familial Atrial Fibrillation, Fibrillation - atrial, ATRIAL FIBRILLATION, Atrial fibrillation, AF - Atrial fibrillation, Atrial ... Atrial, Fibrillation, Auricular, AF, atrial fibrillation, atrial fibrillation (diagnosis), Afib, AFib, Fibrillation atrial, ... Atrial Fibrillation EKG Atrial Fibrillation Rate Control Atrial Fibrillation Rhythm Control Atrial Flutter Atrial Tachycardia ... Atrial Fibrillation Atrial Fibrillation Acute Management Atrial Fibrillation Anticoagulation Atrial Fibrillation Cardioversion ...
more infohttp://fpnotebook.com/CV/EKG/AtrlFbrltn.htm

Atrial Fibrillation | CirculationAtrial Fibrillation | Circulation

Mobile Phone Detection of Atrial Fibrillation With Mechanocardiography: The MODE-AF Study (Mobile Phone Detection of Atrial ... Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial FibrillationShould We Use a CHA2DS2-VA Score ... Atrial Fibrillation Burden in Young Patients With Congenital Heart Disease Zacharias Mandalenakis, Annika Rosengren, Georg ... Treatment of Subclinical Atrial FibrillationDoes One Plus One Always Equal Two? Michael R. Gold ...
more infohttp://circ.ahajournals.org/taxonomy/term/1384

New Procedure Treats Atrial Fibrillation  - RedorbitNew Procedure Treats Atrial Fibrillation - Redorbit

Atrial fibrillation affects more than 2 million Americans, a number that continues to increase as the population ages. While ... Atrial fibrillation occurs when the smaller upper chambers of the heart, called atria, get irregular electrical signals that ... Despite its prevalence, atrial fibrillation remains tricky to treat. Medications that maintain a normal heart rhythm often stop ... If the atrial fibrillation persists, the electrophysiologist can touch up the ablation lines inside the heart until ...
more infohttp://www.redorbit.com/news/health/2071640/new_procedure_treats_atrial_fibrillation/

Nonvalvular atrial fibrillation: Causes and treatmentNonvalvular atrial fibrillation: Causes and treatment

Nonvalvular atrial fibrillation (AF) is a heart condition. Unlike other types of AF, it is not caused by a faulty valve. Causes ... Atrial fibrillation: Which medications. Atrial fibrillation (A-fib) causes a disruption in the regular rhythm of the heart. ... A common cause of atrial fibrillation is valvular heart disease. But what are the reasons for atrial fibrillation other than ... The heart works less efficiently in people with atrial fibrillation.. What does nonvalvular atrial fibrillation mean? ...
more infohttps://www.medicalnewstoday.com/articles/319643.php

Atrial fibrillation: Triggers, tip, and causesAtrial fibrillation: Triggers, tip, and causes

... learn about atrial fibrillation triggers, tips that may help to avoid triggers, lifestyle tips, and what may cause atrial ... What are the types of atrial fibrillation? Atrial fibrillation is an irregular heart rhythm. There are several types of atrial ... Nonvalvular atrial fibrillation: Get the facts Nonvalvular atrial fibrillation (AF) is a heart condition. Unlike other types of ... Atrial fibrillation is an irregular, rapid heartbeat. During an atrial fibrillation attack, the heart might not pump enough ...
more infohttps://www.medicalnewstoday.com/articles/316487.php

Atrial Fibrillation and Pregnancy | The BMJAtrial Fibrillation and Pregnancy | The BMJ

Atrial Fibrillation and Pregnancy. Br Med J 1961; 1 doi: https://doi.org/10.1136/bmj.1.5237.1407 (Published 20 May 1961) Cite ...
more infohttp://www.bmj.com/content/1/5237/1407

Atrial fibrillation - discharge : MedlinePlus Medical EncyclopediaAtrial fibrillation - discharge : MedlinePlus Medical Encyclopedia

Atrial fibrillation or flutter is a common type of abnormal heartbeat. The heart rhythm is fast and most often irregular. You ... Atrial fibrillation or flutter is a common type of abnormal heartbeat. The heart rhythm is fast and most often irregular. You ... Atrial fibrillation: clinical features, mechanisms, and management. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, ... A machine may be less accurate because of atrial fibrillation. Limit the amount of caffeine you drink (found in coffee, tea, ...
more infohttps://medlineplus.gov/ency/patientinstructions/000237.htm

Atrial Fibrillation (AFib) AwarenessAtrial Fibrillation (AFib) Awareness

... through its efforts during Atrial Fibrillation Awareness Month in September and throughout the year, is working to increase ... Atrial Fibrillation - also known as AFib or AF - is the most common arrhythmia. It affects more than 2.5 million American ... The Atrial Fibrillation Disease State Initiative is supported in part by Boehringer Ingelheim, Janssen, Medtronic, and Bristol- ... The AFib Risk Assessment is an interactive tool designed to help individuals estimate their risk of atrial fibrillation (AFib ...
more infohttps://www.hrsonline.org/News/Atrial-Fibrillation-AFib-Awareness

Atrial Fibrillation CausesAtrial Fibrillation Causes

... , Atrial Fibrillation Associated Conditions, Atrial Fibrillation Etiology, Atrial Fibrillation Risk ... Familial Atrial Fibrillation, Fibrillation - atrial, ATRIAL FIBRILLATION, Atrial fibrillation, AF - Atrial fibrillation, Atrial ... Atrial Fibrillation Rate Control Atrial Fibrillation Atrial Fibrillation Cardioversion Atrial Fibrillation EKG Atrial ... Atrial Fibrillation Causes. Atrial Fibrillation Causes Aka: Atrial Fibrillation Causes, Atrial Fibrillation Associated ...
more infohttp://www.fpnotebook.com/CV/EKG/AtrlFbrltnCs.htm

Atrial Fibrillation CardioversionAtrial Fibrillation Cardioversion

... , Ottawa Aggressive Protocol in Atrial Fibrillation Cardioversion, Atrial Flutter ... Familial Atrial Fibrillation, Fibrillation - atrial, ATRIAL FIBRILLATION, Atrial fibrillation, AF - Atrial fibrillation, Atrial ... Atrial, Fibrillation, Auricular, AF, atrial fibrillation, atrial fibrillation (diagnosis), Afib, AFib, Fibrillation atrial, ... Atrial Fibrillation EKG Atrial Fibrillation Rate Control Atrial Fibrillation Rhythm Control Atrial Flutter Atrial Tachycardia ...
more infohttps://fpnotebook.com/cv/EKG/AtrlFbrltnCrdvrsn.htm

Atrial Fibrillation Clinical Research Trials | CenterWatchAtrial Fibrillation Clinical Research Trials | CenterWatch

Atrial Fibrillation Clinical Research Trial Listings in Cardiology/Vascular Diseases on CenterWatch ... Atrial Fibrillation Clinical Trials. A listing of Atrial Fibrillation medical research trials actively recruiting patient ... Systematic Evaluation of Ablation Techniques for Non-Paroxysmal Atrial Fibrillation. The Posterior Wall and/or Left Atrial ... strategies of atrial fibrillation in patients with coronary artery disease and without history of atrial fibrillation. The ...
more infohttps://www.centerwatch.com/clinical-trials/listings/condition/243/atrial-fibrillation/?NewOnly=Y&gender=Both&gender=Both

Mechanisms of thrombogenesis in atrial fibrillationMechanisms of thrombogenesis in atrial fibrillation

This complication can occur with either paroxysmal (intermittent) or chronic (permanent) atrial fibrillation. A numb ... Atrial fibrillation (AF) is associated with substantial mortality and morbidity, largely due to thromboembolism, particularly ... Antithrombotic treatment for atrial fibrillation. BMJ 1996; 312:45.. *Lip GY. Does atrial fibrillation confer a hypercoagulable ... patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation ...
more infohttps://www.uptodate.com/contents/mechanisms-of-thrombogenesis-in-atrial-fibrillation

Atrial FibrillationAtrial Fibrillation

... you may have a condition known as atrial fibrillation. Atrial fibrillation (also called AFib) is a problem with the rate or ... Living with Atrial Fibrillation Event in Pueblo, Colo.. Oct 16, 2014. This series of live educational programs provides ... Living with Atrial Fibrillation Event in Columbus, Ohio. Sep 22, 2014. This series of live educational programs provides ... Living with Atrial Fibrillation Event in Minneapolis. Oct 16, 2014. This series of live educational programs provides ...
more infohttps://www.cardiosmart.org/Heart-Conditions/Atrial-Fibrillation?page=5&pagesize=25
  • It is probable that in some of these patients, the atria remodel over a period of time (see below), owing to the frequent recurrence of fast atrial rates, and develop sustained atrial fibrillation, which is then much more difficult to cure with RFCA. (ahajournals.org)
  • During an atrial fibrillation attack, the heart might not pump enough oxygen-rich blood to the rest of the body, leading to symptoms including weakness, light-headedness, and dizziness. (medicalnewstoday.com)
  • In atrial fibrillation, the upper chambers of the heart (the atria) beat irregularly (quiver) instead of beating effectively to move blood into the ventricles. (stvincent.org)
  • A listing of Atrial Fibrillation medical research trials actively recruiting patient volunteers. (centerwatch.com)
  • They also note the amount of time a patient is in atrial fibrillation. (healthcentral.com)
  • Sign Against Stroke - Patient organisations from twenty countries produced the Global Atrial Fibrillation Charter. (wikipedia.org)
  • This complication can occur with either paroxysmal (intermittent) or chronic (permanent) atrial fibrillation. (uptodate.com)
  • See 'Atrial fibrillation: Anticoagulant therapy to prevent embolization' and 'Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation' . (uptodate.com)
  • Atrial fibrillation is the most common type of sustained abnormal heart rhythm (arrhythmia), affecting more than 3 million people in the United States. (wikipedia.org)
  • Renal dysfunction is an independent risk factor for stroke, especially in the setting of atrial fibrillation (AF), and adding it as a scoring element to current risk stratification models, such as CHADS2 , seems to improve stroke risk prediction. (medpagetoday.com)
  • It is associated with multiple genes: Mutations in the KCNQ1 gene cause familial atrial fibrillation. (wikipedia.org)
  • A small percentage of all cases of familial atrial fibrillation are associated with changes in the KCNE2, KCNJ2, and KCNQ1 genes. (wikipedia.org)
  • The mutations known to be possibly involved in atrial fibrillation concern KCNQ1 with gain of function in IKs, KCNE2, KCNA5 and SCN5A for which there is a missence mutation leading to the occurrence of Early After Depolarisations. (escardio.org)
  • Atrial fibrillation: clinical features, mechanisms, and management. (medlineplus.gov)
  • The session devoted to new insights in atrial fibrillation showed that a great number of mechanisms may be involved in atrial fibrillation. (escardio.org)
  • Atrial fibrillation affects more than 2 million Americans, a number that continues to increase as the population ages. (redorbit.com)
  • After the surgeon has performed the ablations on the outside of the heart, the electrophysiologist uses the catheters inside the heart to attempt to induce a fibrillation, testing the integrity of the ablation lines. (redorbit.com)
  • Gelsolin may be considered as a possible proarrhythmic factor, able to induce atrial fibrillation in mice. (escardio.org)
  • Today there are many ways to treat and control atrial fibrillation including medications and procedures. (hrsonline.org)
  • Familial atrial fibrillation appears to be inherited in an autosomal dominant pattern, which means the defective gene is located on an autosome, and only one copy of the defective gene - inherited from one parent - is sufficient to cause the disorder. (wikipedia.org)
  • Disturbed actin modulation may promote atrial fibrillation and desmin deficiency increases atrial fibrillation inducibility. (escardio.org)
  • This guideline updates and replaces 'Atrial fibrillation' (NICE clinical guideline 36). (nice.org.uk)